

Guidelines on Male Infertility

A.Jungwirth (Chair), T. Diemer, G.R Dohle, A. Giwercman,
Z. Kopa, C.Krausz, H. Tournaye

TABLE OF CONTENTS

PAGE

1.	INTRODUCTION	5
	1.1 Aim	5
	1.2 Publication history	5
	1.3 Panel composition	5
2.	METHODS	5
3.	THE GUIDELINE	6
3A	MALE INFERTILITY	6
	3A.1 Epidemiology and aetiology	6
	3A.1.1 Prognostic factors	7
	3A.1.2 Recommendations on epidemiology and aetiology	7
	3A.2 Diagnostic evaluation	7
	3A.2.1 Semen analysis	7
	3A.2.1.1 Frequency of semen analysis	8
	3A.2.2 Recommendations for the diagnostic evaluation of male infertility	8
3B	PRIMARY SPERMATOGENIC FAILURE	8
	3B.1 Aetiology	8
	3B.2 Diagnostic evaluation	9
	3B.2.1 Semen analysis	9
	3B.2.2 Hormonal determinations	9
	3B.2.3 Testicular biopsy	9
	3B.3 Conclusions and recommendations for testicular deficiency	10
3C	GENETIC DISORDERS IN INFERTILITY	10
	3C.1 Chromosomal abnormalities	10
	3C.1.1 Sex chromosome abnormalities (Klinefelter's syndrome and variants [47,XXY; 46,XY/47, XXY mosaicism])	11
	3C.1.2 Autosomal abnormalities	11
	3C.1.3 Sperm chromosomal abnormalities	11
	3C.2 Genetic defects	11
	3C.2.1 X-linked genetic disorders and male fertility	11
	3C.2.2 Kallmann syndrome	12
	3C.2.3 Mild androgen insensitivity syndrome	12
	3C.2.4 Other X-disorders	12
	3C.3 Y-chromosome and male infertility	12
	3C.3.1 Clinical implications of Y microdeletions	12
	3C.3.1.1 Testing for Y microdeletions	13
	3C.3.1.2 Genetic counselling for AZF deletions	13
	3C.3.1.3 Y-chromosome: 'gr/gr' deletion	13
	3C.3.1.4 Autosomal defects with severe phenotypic abnormalities and infertility	13
	3C.4 Cystic fibrosis mutations and male infertility	13
	3C.4.1 Unilateral or bilateral absence/abnormality of the vas and renal anomalies	14
	3C.4.2 Unknown genetic disorders	14
	3C.4.3 DNA fragmentation in spermatozoa	14
	3C.4.4 Genetic counselling and ICSI	14
	3C.5 Conclusions and recommendations for genetic disorders in male infertility	15
3D	OBSTRUCTIVE AZOOSPERMIA	15
	3D.1 Classification	15
	3D.1.1 Intratesticular obstruction	15
	3D.1.2 Epididymal obstruction	15
	3D.1.3 Vas deferens obstruction	16
	3D.1.4 Ejaculatory duct obstruction	16
	3D.1.5 Functional obstruction of the distal seminal ducts	16
	3D.2 Diagnostic evaluation	16
	3D.2.1 Clinical history	16
	3D.2.2 Clinical examination	16
	3D.2.3 Semen analysis	16
	3D.2.4 Hormone levels	16

	3D.2.5	Ultrasonography	16
	3D.2.6	Testicular biopsy	17
3D.3		Disease management	17
	3D.3.1	Intratesticular obstruction	17
	3D.3.2	Epididymal obstruction	17
	3D.3.3	Proximal vas obstruction	17
	3D.3.4	Distal vas deferens obstruction	17
	3D.3.5	Ejaculatory duct obstruction	17
3D.4		Conclusions and recommendation for obstructive azoospermia	17
3E		VARICOCELE	18
	3E.1	Classification	18
	3E.2	Diagnostic evaluation	18
	3E.3	Basic considerations	18
	3E.3.1	Varicocele and fertility	18
	3E.3.2	Varicocelectomy	18
	3E.4	Disease management	18
	3E.5	Conclusions and recommendations for varicocele	19
3F		HYPOGONADISM	20
	3F.1	Epidemiology and aetiology	20
	3F.2	Idiopathic hypogonadotrophic hypogonadism: aetiology, diagnosis and therapeutic management	20
	3F.3	Hypergonadotrophic hypogonadism: aetiology, diagnosis and therapeutic management	21
	3F.4	Conclusion and recommendations for hypogonadism	21
3G		CRYPTORCHIDISM	21
	3G.1	Aetiology and pathophysiology	21
	3G.1.1	Incidence of cryptorchidism	22
	3G.1.2	Pathophysiological effects in maldescended testes	22
	3G.1.2.1	Degeneration of germ cells	22
	3G.1.2.2	Relationship with fertility	22
	3G.1.2.3	Germ cell tumours	22
	3G.2	Disease management	22
	3G.2.1	Hormonal treatment	22
	3G.2.2	Surgical treatment	22
	3G.3	Conclusions and recommendations for cryptorchidism	23
3H		IDIOPATHIC MALE INFERTILITY	23
	3H.1	Disease management	23
	3H.1.1	Empirical treatments	23
	3H.2	Recommendation for idiopathic male infertility	23
3I		MALE CONTRACEPTION	24
	3I.1	Vasectomy	24
	3I.1.1	Surgical techniques	24
	3I.1.2	Complications	24
	3I.1.3	Vasectomy failure	24
	3I.1.4	Counselling	24
	3I.2	Vasectomy reversal	24
	3I.2.1	Length of time since vasectomy	25
	3I.2.2	Tubulovasostomy	25
	3I.2.3	Microsurgical vasectomy reversal vs. epididymal or testicular sperm retrieval and ICSI	25
	3I.3	Conclusions and recommendations for male contraception	25
3J		MALE ACCESSORY GLAND INFECTIONS AND INFERTILITY	25
	3J.2	Diagnostic evaluation	26
	3J.2.1	Ejaculate analysis	26
	3J.2.1.1	Microbiological findings	26
	3J.2.1.2	White blood cells	26
	3J.2.1.3	Sperm quality	26
	3J.2.1.4	Seminal plasma alterations	26
	3J.2.1.5	Glandular secretory dysfunction	26
	3J.2.1.6	Reactive oxygen species	26
	3J.2.2	Disease management	26

	3J.3	Epididymitis	27
	3J.3.1	Diagnostic evaluation	27
	3J.3.3.1	Ejaculate analysis	27
	3J.3.2	Disease management	27
	3J.4	Conclusions and recommendations for male accessory gland infections	27
3K		GERM CELL MALIGNANCY AND TESTICULAR MICROCALCIFICATION	27
	3K.1	Germ cell malignancy and male infertility	27
	3K.2	Testicular germ cell cancer and reproductive function	28
	3K.3	Testicular microlithiasis	28
	3K.4	Recommendations for germ cell malignancy and testicular microcalcification	28
3L		DISORDERS OF EJACULATION	29
	3L.1	Classification and aetiology	29
	3L.1.1	Anejaculation	29
	3L.1.2	Anorgasmia	29
	3L.1.3	Delayed ejaculation	29
	3L.1.4	Retrograde ejaculation	29
	3L.1.5	Asthenic ejaculation	29
	3L.1.6	Premature ejaculation	29
	3L.2	Diagnostic evaluation	30
	3L.2.1	Clinical history	30
	3L.2.2	Physical examination	30
	3L.2.3	Post-ejaculatory urinalysis	30
	3L.2.4	Microbiological examination	30
	3L.2.5	Optional diagnostic work-up	30
	3L.3	Disease management	30
	3L.3.1	Aetiological treatment	30
	3L.3.2	Symptomatic treatment	30
	3J.3.2.1	Premature ejaculation	30
	3L.3.2.2	Retrograde ejaculation	31
	3L.3.2.3	Anejaculation	31
	3L.4	Conclusion and recommendations for disorders of ejaculation	31
3M		SEMEN CRYOPRESERVATION	31
	3M.1	Indications for storage	32
	3M.2	Precautions and techniques	32
	3M.2.1	Freezing and thawing process	32
	3M.2.2	Cryopreservation of small numbers of sperm	32
	3M.2.3	Testing for infections and preventing cross-contamination	32
	3M.2.4	Fail-safe precautions to prevent loss of stored materials	33
	3M.2.5	Orphan samples	33
	3M.3	Biological aspects	33
	3M.4	Conclusions and recommendations for semen cryopreservation	33
4.		REFERENCES	34
5.		CONFLICT OF INTEREST	47

1. INTRODUCTION

1.1 Aim

The European Association of Urology (EAU) Guidelines Panel on Male Infertility has prepared these Guidelines to assist urologists and healthcare professionals from related specialties in the treatment of male infertility. Urologists are usually the specialists who are initially responsible for assessing the male when male infertility is suspected. However, infertility can be a multifactorial condition requiring multidisciplinary involvement.

1.2 Publication history

The EAU Male Infertility Guidelines were first published in 2001, followed by full-text updates in 2004, 2007, 2010, 2013 and 2014.

In this 2015 version the text has been significantly reduced so that only key information is included and re-formatted according to the EAU template for non-oncology Guidelines, so that all Guidelines follow a similar format.

A quick reference document (Pocket Guidelines) is available, both in print and in a number of versions for mobile devices, presenting the main findings of the Male Infertility Guidelines. These are abridged versions which may require consultation together with the full text versions. The Male Infertility Panel published a number of scientific publications in the EAU journal *European Urology* [1-3]. A separate scientific paper on Vasectomy was published in 2012 [3]. All texts can be viewed and downloaded for personal use at the society website: <http://www.uroweb.org/guidelines/online-guidelines/>.

This document was peer-reviewed prior to publication.

1.3 Panel composition

The Male Infertility Guidelines Panel consists of urologists, endocrinologists and gynaecologists with special training in andrology and experience in the diagnosis and treatment of male infertility.

2. METHODS

References used in this text are graded according to their Level of Evidence (LE) and Guidelines are given a Grade of Recommendation (GR). In this 2015 EAU Guidelines compilation, all standard information on LE and GR has been taken out of the individual Guidelines topics for the sake of brevity. The methodology section (see the introduction chapter of the complete book) outlines the LE and GR criteria which are used throughout the Guidelines, according to a classification system modified from the Oxford Centre for Evidence-based Medicine Levels of Evidence.

The recommendations provided in these guidelines are based on a systematic literature search performed by the panel members. The controlled vocabulary of the MeSH database was used alongside a free text protocol, combining “male infertility” with the terms “diagnosis”, “epidemiology”, “investigations”, “treatment”, “spermatogenic failure”, “genetic abnormalities”, “obstruction”, “hypogonadism”, “varicocele”, “cryptorchidism”, “testicular cancer”, “male accessory gland infection”, “idiopathic”, “contraception”, “ejaculatory dysfunction”, and “cryopreservation”.

For the 2014 print a scoping search was done covering 2012 and 2013, with a cut-off date of September 2013. Embase, Medline and the Cochrane Central Register of Controlled Trials were searched, with a limitation to reviews, meta-analysis or meta-analysis of RCTs. After de-duplication 447 unique records were identified, of which five publications were selected for inclusion.

3. THE GUIDELINE

3A MALE INFERTILITY

Definition

“Infertility is the inability of a sexually active, non-contracepting couple to achieve spontaneous pregnancy in one year”, World Health Organization (WHO) [4].

3A.1 Epidemiology and aetiology

About 15% of couples do not achieve pregnancy within one year and seek medical treatment for infertility. One in eight couples encounter problems when attempting to conceive a first child and one in six when attempting to conceive a subsequent child. Three percent of women remain involuntarily childless, while 6% of parous women are not able to have as many children as they would wish [5]. Infertility affects both men and women. In 50% of involuntarily childless couples, a male-infertility-associated factor is found together with abnormal semen parameters. A fertile partner may compensate for the fertility problem of the man and thus infertility usually manifests if both partners have reduced fertility [4]. Male fertility can be reduced as a result of [4]:

- congenital or acquired urogenital abnormalities;
- malignancies;
- urogenital tract infections;
- increased scrotal temperature (e.g. as a consequence of varicocele);
- endocrine disturbances;
- genetic abnormalities;
- immunological factors.

In 30-40% of cases, no male-infertility-associated factor is found (idiopathic male infertility). These men present with no previous history of diseases affecting fertility and have normal findings on physical examination and endocrine, genetic and biochemical laboratory testing. However, semen analysis might reveal pathological findings in the spermogram (see 3A.2.1). Table 1 summarises the main male-infertility-associated factors. Idiopathic male infertility is assumed to be caused by several factors, including endocrine disruption as a result of environmental pollution, reactive oxygen species, or genetic and epigenetic abnormalities.

Table 1: Male infertility causes and associated factors and percentage of distribution in 10,469 patients [6]

Diagnosis	Unselected patients (n = 12,945)	Azoospermic patients (n = 1,446)
<i>All</i>	100%	11.2%
<i>Infertility of known (possible) cause</i>	42.6%	42.6%
Mal descended testes	8.4	17.2
Varicocele	14.8	10.9
Sperm autoantibodies	3.9	-
Testicular tumour	1.2	2.8
Others	5.0	1.2
<i>Idiopathic infertility</i>	30.0	13.3
<i>Hypogonadism</i>	10.1	16.4
Klinefelter's syndrome (47, XXY)	2.6	13.7
XX male	0.1	0.6
Primary hypogonadism of unknown cause	2.3	0.8
Secondary (hypogonadotropic) hypogonadism	1.6	1.9
Kallmann syndrome	0.3	0.5
Idiopathic hypogonadotrophic hypogonadism	0.4	0.4
Residual after pituitary surgery	<0.1	0.3
Others	0.8	0.8
Late-onset hypogonadism	2.2	-
Constitutional delay of puberty	1.4	-
<i>General/systemic disease</i>	2.2	0.5
<i>Cryopreservation due to malignant disease</i>	7.8	12.5
Testicular tumour	5.0	4.3
Lymphoma	1.5	4.6

Leukaemia	0.7	2.2
Sarcoma	0.6	0.9
<i>Disturbance of erection/ejaculation</i>	2.4	-
<i>Obstruction</i>	2.2	10.3
Vasectomy	0.9	5.3
Cystic fibrosis (CBAVD)	0.5	3.1
Others	0.8	1.9

3A.1.1 **Prognostic factors**

Prognostic factors for male infertility are:

- duration of infertility
- primary or secondary infertility
- results of semen analysis and
- age and fertility status of female partner.

The cumulative pregnancy rate is 27% in infertile couples with 2 years of follow-up and oligozoospermia as the primary cause of infertility [7]. Female age is the most important single variable influencing outcome in assisted reproduction [8]. Compared to a woman aged 25 years, the fertility potential of a woman aged 35 years is reduced to 50%, to 25% at 38 years, and less than 5% at over 40 years. In many Western countries, women postpone their first pregnancy until after their education and starting a career.

3A.1.2 **Recommendations on epidemiology and aetiology**

Recommendations	GR
To categorise infertility, both partners should be investigated simultaneously.	C
In the diagnosis and management of male subfertility, the fertility status of the female partner must also be considered, because this might determine the final outcome [5].	B
The urologist/andrologist should examine any man with fertility problems for urogenital abnormalities. This applies to all men diagnosed with abnormal semen parameters. A diagnosis (even if idiopathic) is mandatory to start appropriate therapy (drugs, surgery, or assisted reproduction).	C

3A.2 **Diagnostic evaluation**

3A.2.1 **Semen analysis**

A medical history and physical examination are standard assessments in all men, including semen analysis. A comprehensive andrological examination is indicated if semen analysis shows abnormalities compared with reference values (Table 2). Important treatment decisions are based on the results of semen analysis, therefore, it is essential that the complete laboratory work-up is standardised. Ejaculate analysis has been standardised by the WHO and disseminated by publication of the WHO Laboratory Manual for the Examination and Processing of Human Semen (5th edn.) [9]. It is the consensus that modern spermatology must follow these guidelines.

Table 2: Lower reference limits (5th centiles and their 95% CIs) for semen characteristics

Parameter	Lower reference limit (range)
Semen volume (mL)	1.5 (1.4-1.7)
Total sperm number (10 ⁶ /ejaculate)	39 (33-46)
Sperm concentration (10 ⁶ /mL)	15 (12-16)
Total motility (PR + NP)	40 (38-42)
Progressive motility (PR, %)	32 (31-34)
Vitality (live spermatozoa, %)	58 (55-63)
Sperm morphology (normal forms, %)	4 (3.0-4.0)
Other consensus threshold values	
pH	> 7.2
Peroxidase-positive leukocytes (10 ⁶ /mL)	< 1.0
Optional investigations	
MAR test (motile spermatozoa with bound particles, %)	< 50
Immunobead test (motile spermatozoa with bound beads, %)	< 50
Seminal zinc (µmol/ejaculate)	≥ 2.4
Seminal fructose (µmol/ejaculate)	≥ 13
Seminal neutral glucosidase (mU/ejaculate)	≤ 20

CIs = confidence intervals; MAR = mixed antiglobulin reaction NP = non-progressive; PR = progressive.

3A.2.1.1 Frequency of semen analysis

If the results of semen analysis are normal according to WHO criteria, one test is sufficient. If the results are abnormal in at least two tests, further andrological investigation is indicated. It is important to differentiate between the following:

- oligozoospermia: spermatozoa < 15 million/mL;
- asthenozoospermia: < 32% progressive motile spermatozoa;
- teratozoospermia: < 4% normal forms.

Often, all three anomalies occur simultaneously, which is defined as oligo-asteno-teratozoospermia (OAT) syndrome. As in azoospermia, in extreme cases of oligozoospermia (spermatozoa < 1 million/mL), there is an increased incidence of obstruction of the male genital tract and genetic abnormalities.

3A.2.2 Recommendations for the diagnostic evaluation of male infertility

Recommendations	GR
According to WHO criteria, andrological investigations are indicated if semen analysis is abnormal in at least two tests to define a diagnosis.	A*
Diagnosis and evaluation of male subfertility according to the WHO Manual for the standardised investigation, diagnosis and management of the infertile male is recommended [10].	C
Semen analysis must follow the guidelines of the WHO Laboratory Manual for the Examination and Processing of Human Semen (5th edn.) [9].	A*
The WHO laboratory manual proposes reference values based on fertility, hence, these reference values do not allow to classify a man as being infertile.	A

*Upgraded following panel consensus.

3B PRIMARY SPERMATOGENIC FAILURE

Testicular deficiency as a consequence of primary spermatogenic failure is caused by conditions other than hypothalamic-pituitary disease and obstruction of the male genital tract. It is the commonest form of reduced male fertility. Testicular deficiency may have different aetiologies and present clinically as severe OAT or non-obstructive azoospermia (NOA) [10].

3B.1 Aetiology

The causes of testicular deficiency are summarised in Table 3.

Table 3: Causes of testicular deficiency

Factors	Causes
Congenital	Anorchia
	Testicular dysgenesis/cryptorchidism
	Genetic abnormalities (karyotype, Y-chromosome deletions)
Acquired	Trauma
	Testicular torsion
	Post-inflammatory forms, particularly mumps orchitis
	Exogenous factors (medications, cytotoxic or anabolic drugs, irradiation, heat)
	Systemic diseases (liver cirrhosis, renal failure)
	Testicular tumour
	Varicocele
Idiopathic	Surgery that may compromise vascularisation of the testes and lead to testicular atrophy
	Unknown aetiology
	Unknown pathogenesis

3B.2 Diagnostic evaluation

Routine investigations include semen analysis and hormonal determinations. Other investigations may be required depending on the individual situation.

Typical findings from the history and physical examination of a patient with testicular deficiency are:

- cryptorchidism (uni- or bilateral)
- testicular torsion
- genitourinary infection
- testicular trauma
- exposure to environmental toxins
- gonadotoxic medication including anabolic drugs
- exposure to radiation or cytotoxic agents
- testicular cancer
- absence of testes
- abnormal secondary sexual characteristics
- gynaecomastia
- abnormal testicular volume and/or consistency
- varicocele.

3B.2.1 Semen analysis

In NOA, semen analysis shows normal ejaculate volume and azoospermia after centrifugation. A recommended method is semen centrifugation at 3000 g for 15 min and a thorough microscopic examination by phase contrast optics at $\times 200$ magnification of the pellet. All samples can be stained and re-examined microscopically [9].

3B.2.2 Hormonal determinations

In men with testicular deficiency, hypergonadotrophic hypogonadism is usually present, with high levels of follicle-stimulating hormone (FSH) and luteinising hormone (LH), and sometimes low levels of testosterone. Generally, the levels of FSH correlate with the number of spermatogonia: when spermatogonia are absent or markedly diminished, FSH values are usually elevated; when the number of spermatogonia is normal, but maturation arrest exists at the spermatocyte or spermatid level, FSH values are within the normal range. However, for an individual patient, FSH levels do not accurately predict the spermatogenesis status because men with maturation arrest histology could have normal FSH and normal testis volume and still be azoospermic [11, 12].

3B.2.3 Testicular biopsy

Testicular biopsy can be part of intracytoplasmic sperm injection (ICSI) treatment in patients with clinical evidence of NOA. Testicular sperm extraction (TESE) is the technique of choice. Spermatogenesis may be focal, which means that in about 50% of men with NOA, spermatozoa can be found and used for ICSI. Most authors therefore recommend taking several testicular samples. There is a good correlation between the histology found upon diagnostic biopsy and the likelihood of finding mature sperm cells during testicular sperm retrieval and ICSI [13-15]. However, no threshold value has been found for FSH, inhibin B, or testicular volume

and successful sperm harvesting. When there are complete AZFa and AZFb microdeletions, the likelihood of sperm retrieval is virtually zero and therefore TESE procedures are contraindicated. Microsurgical TESE increases retrieval rates vs. conventional TESE, and should be preferred in severe cases of non-obstructive azoospermia [16-19]. Positive retrievals are reported even in conditions such as Sertoli cell only syndrome type II [10].

The results of ICSI are worse when using sperm retrieved from men with NOA compared to sperm from ejaculated semen and from men with obstructive azoospermia (OA) [20-24]. Birth rates are lower in NOA vs. OA (19% vs 28%) [25].

- ICSI results in significantly lower fertilisation and implantation rates.
- Neonatal health in terms of birth parameters, major anomalies and chromosomal aberrations in a large cohort of children born after use of non-ejaculated sperm, are comparable to the outcome of children born after use of ejaculated sperm [26].

3B.3 Conclusions and recommendations for testicular deficiency

Conclusions	LE
Impaired spermatogenesis is often associated with elevated FSH concentration.	3
Spermatozoa are found in about 50% of patients with NOA.	2a
Pregnancies and live births are eventually obtained in 30-50% of couples with NOA, when spermatozoa have been found in the testicular biopsy.	3

Recommendations	GR
Men who are candidates for sperm retrieval must receive appropriate genetic counselling.	A
Testicular biopsy is the best procedure to define the histological diagnosis and retrieve sperm in the same procedure. Spermatozoa have to be cryopreserved for use in ICSI.	A
For patients with NOA who have spermatozoa in their testicular biopsy, ICSI with fresh or cryopreserved spermatozoa is the only therapeutic option.	A
Men with NOA can be offered TESE with cryopreservation of the spermatozoa to be used for ICSI [27].	A
To increase the chances of positive sperm retrieval in men with NOA, TESE (microsurgical or multiple) should be used.	A

ICSI = intracytoplasmic sperm injection; TESE = testicular sperm extraction; NOA = non-obstructive azoospermia.

3C GENETIC DISORDERS IN INFERTILITY

All urologists working in andrology must have an understanding of genetic abnormalities associated with infertility, so that they can provide correct advice to couples seeking fertility treatment. Men with very low sperm counts can be offered a reasonable chance of paternity, using in vitro fertilisation (IVF), ICSI, and sperm harvesting from the testes in case of azoospermia. However, the spermatozoa of infertile men show an increased rate of aneuploidy, structural chromosomal abnormalities, and DNA damage, carrying the risk of passing genetic abnormalities to the next generation. Current routine clinical practice is based on the screening of genomic DNA from peripheral blood samples, however, screening of chromosomal anomalies in spermatozoa is also feasible and can be performed in selected cases [28].

3C.1 Chromosomal abnormalities

Chromosome abnormalities can be numerical (e.g. trisomy) or structural (e.g. inversions or translocations). In a survey of pooled data from 11 publications, including 9,766 infertile men, the incidence of chromosomal abnormalities was 5.8% [29]. Of these, sex chromosome abnormalities accounted for 4.2% and autosomal abnormalities for 1.5%. In comparison, the incidence of abnormalities was 0.38% in pooled data from three series, with a total of 94,465 newborn male infants, of which 131 (0.14%) were sex chromosome abnormalities and 232 (0.25%) autosomal abnormalities [29]. The frequency of chromosomal abnormalities increases as testicular deficiency becomes more severe. Patients with a spermatozoa count < 5 million/mL already show a 10-fold higher incidence (4%) of mainly autosomal structural abnormalities compared with the general population [30, 31]. Men with NOA are at highest risk, especially for sex chromosomal anomalies.

Based on the frequencies of chromosomal aberrations in patients with different sperm concentration, karyotype analysis is indicated in men with azoospermia or oligozoospermia (spermatozoa < 10 million/mL) [31]. A recent study proposes to restrict karyotype to NOA men with the purpose to prevent adverse pregnancy outcomes [32]. If there is a family history of recurrent spontaneous abortions, malformations or mental retardation, karyotype analysis should be requested, regardless of the sperm concentration.

3C.1.1 Sex chromosome abnormalities (Klinefelter's syndrome and variants [47,XXY; 46,XY/47,XXY mosaicism])

Klinefelter's syndrome is the most common sex chromosome abnormality [29, 33]. Adult men with Klinefelter's syndrome have small firm testicles, devoid of germ cells. The phenotype varies from a normally virilised man to one with the stigmata of androgen deficiency, including female hair distribution, scant body hair, and long arms and legs due to late epiphyseal closure. Leydig cell function is commonly impaired in men with Klinefelter's syndrome [34]. Testosterone levels may be normal or low, oestradiol levels normal or elevated, and FSH levels increased. Libido is often normal despite low testosterone levels, but androgen replacement may be needed as the patient ages.

Germ cell presence and sperm production are variable in men with Klinefelter's mosaicism, 46,XY/47,XXY. Based on sperm fluorescence in situ hybridisation (FISH) studies showing an increased frequency of sex chromosomal abnormalities and increased incidence of autosomal aneuploidy (disomy for chromosomes 13, 18 and 21), concerns have been raised about the chromosomal normality of the embryos generated through ICSI [35].

The production of 24,XY sperm has been reported in 0.9% and 7.0% of men with Klinefelter's mosaicism [36, 37] and in 1.36-25% of men with somatic karyotype 47,XXY [38-41]. In patients with azoospermia, TESE or (micro-TESE) can be proposed as a therapeutic option since spermatozoa can be recovered in about 30% of cases. Numerous healthy children have been born using ICSI without pre-implantation genetic diagnosis (PGD) and the conception of one 47,XXY foetus has been reported [33]. However, a study of ICSI combined with PGD in 113 embryos reported a significant fall in the rate of normal embryos for couples with Klinefelter's syndrome with respect to controls (54% vs. 77.2%) [41]. Due to the significant increase of sex chromosomal and autosomal abnormalities in the embryos of Klinefelter's patients, PGD or amniocentesis analysis should be considered.

Follow-up (possibly every year) of men with Klinefelter's syndrome is required and androgen replacement therapy should be started after fertility issues have been addressed and when testosterone level is in the range of hypoandrogenism.

3C.1.2 Autosomal abnormalities

Genetic counselling should be offered to all couples seeking fertility treatment (including IVF/ICSI) when the male partner has an autosomal karyotype abnormality. The most common autosomal karyotype abnormalities are Robertsonian translocations, reciprocal translocations, paracentric inversions, and marker chromosomes. It is important to look for these structural chromosomal anomalies because there is an increased associated risk of aneuploidy or unbalanced chromosomal complements in the foetus. As with Klinefelter's syndrome, sperm FISH analysis provides a more accurate risk estimation of affected offspring, however, the diffusion of this genetic test is largely limited by the availability of laboratories able to perform this analysis.

When IVF/ICSI is carried out for men with translocations, PGD or amniocentesis should be performed.

3C.1.3 Sperm chromosomal abnormalities

Sperm can be examined for their chromosomal constitution using multicolour FISH both in men with normal karyotype and with anomalies. Aneuploidy in sperm, particularly sex chromosome aneuploidy, is associated with severe damage to spermatogenesis [29, 42-44] and with translocations [45].

Florescence in situ hybridisation analysis of spermatozoa is only indicated for specific andrology conditions e.g. macrocephalia [44].

3C.2 Genetic defects

3C.2.1 X-linked genetic disorders and male fertility

Each man has only one X-chromosome. An X-linked recessive disorder manifests in males. The defect will be transmitted to daughters, but not to sons.

3C.2.2 **Kallmann syndrome**

Patients with Kallmann syndrome have hypogonadotrophic hypogonadism and anosmia, but may also have other clinical features, including facial asymmetry, cleft palate, colour blindness, deafness, maldescended testes, and unilateral renal aplasia. This syndrome can be due to mutation in the Kalig-1 gene [on the X-chromosome] or in several other autosomal genes and should be tested [44,45].

Spermatogenesis can be relatively easily induced by hormonal treatment [46], therefore, genetic screening prior to therapy is advisable although it is limited by the rarity of specialised genetic laboratories that can offer this genetic test. Treatment with gonadotropins allows natural conception in most cases, even for men with a relatively low sperm count. Thus, identification of the involved gene (X-linked, autosomal dominant or recessive) can help to provide more accurate genetic counselling, that is, risk estimation for transmission to the offspring.

3C.2.3 **Mild androgen insensitivity syndrome**

The AR gene is located on the long arm of the X-chromosome. Mutations in the AR gene may result in mild to complete androgen insensitivity. The phenotypic features of complete androgen insensitivity syndrome are female external genitalia and absence of pubic hair (Morris syndrome). In partial androgen insensitivity syndrome, phenotypes range from predominantly female phenotype through ambiguous genitalia, to predominantly male phenotype with micropenis, perineal hypospadias, and cryptorchidism. The latter phenotype is also termed Reifenstein syndrome. In the forementioned severe forms of androgen resistance, there is no risk of transmission because affected men cannot generate their own biological children using the current technologies. Patients with mild androgen insensitivity syndrome have male infertility as their primary or even sole symptom. Disorders of the androgen receptor causing infertility in the absence of any genital abnormality are rare, and only a few mutations have been reported in infertile [47-50] or fertile [51] men.

3C.2.4 **Other X-disorders**

An unexpectedly high number of genes with a testis-specific or enriched expression pattern have been identified on the X-chromosome, and in particular, premeiotic genes are over-represented on the X-chromosome compared with autosomal chromosomes [52]. Nevertheless, to date only a few genes have been screened in relatively small populations and none of them appear relevant for male infertility [53, 54]. On the other hand, two recent independent studies showed a significantly higher deletion load on the X-chromosome in men with spermatogenic failure with respect to normozoospermic controls [55, 56].

3C.3 **Y-chromosome and male infertility**

Microdeletions on the Y-chromosome are termed AZFa, AZFb and AZFc [57]. Clinically relevant deletions remove partially, or in most cases completely, one or more of the AZF regions, and are the most frequent molecular genetic cause of severe oligozoospermia and azoospermia [58]. In each AZF region, there are several spermatogenesis candidate genes [59]. Deletions occur en bloc (i.e. removing more than one gene), thus, it is not possible to determine the role of a single AZF gene from the AZF deletion phenotype and it is unclear if they all participate in spermatogenesis. Gene-specific deletions, which remove a single gene, have been reported only in the AZFa region and concern the USP9Y gene. These studies have suggested that USP9Y is most likely to be a “fine tuner” of sperm production, and its specific screening is not advised [60].

3C.3.1 **Clinical implications of Y microdeletions**

The clinical significance of Yq microdeletions can be summarised as follows:

- They are not found in normozoospermic men, proving there is a clear cut cause-and-effect relationship between Y-deletions and spermatogenic failure [61].
- The highest frequency of Y-deletions is found in azoospermic men (8-12%), followed by oligozoospermic (3-7%) men.
- Deletions are extremely rare with a sperm concentration > 5 million/mL (~0.7%).
- AZFc deletions are most common (65-70%), followed by Y-deletions of the AZFb and AZFb+c or AZFa+b+c regions (25-30%). AZFa region deletions are rare (5%).
- Complete removal of the AZFa region is associated with severe testicular phenotype (Sertoli cell only syndrome), while complete removal of the AZFb region is associated with spermatogenic rest. Complete removal of the AZFc region causes a variable phenotype ranging from azoospermia to oligozoospermia.
- Classical (complete) AZF deletions do not confer a risk for cryptorchidism or testicular cancer [58].

The specificity and genotype/phenotype correlation reported above means that Y-deletion analysis has both a diagnostic and prognostic value for testicular sperm retrieval [58].

3C.3.1.1 Testing for Y microdeletions

Indications for AZF deletion screening are based on sperm count and include azoospermia and severe oligozoospermia (spermatozoa count < 5 million/mL). Thanks to the European Academy of Andrology (EAA) guidelines [62] and the EAA/EMQN (European Molecular Genetics Quality Network) external quality control programme (<http://www.emqn.org/emqn/>), Yq testing has become more reliable in different routine genetic laboratories. The EAA guidelines provide a set of primers capable of detecting > 95% of clinically relevant deletions [62].

3C.3.1.2 Genetic counselling for AZF deletions

After conception, any Y-deletions are transmitted obligatorily to the male offspring, and genetic counselling is therefore mandatory. In most cases, father and son have the same microdeletion [62], but occasionally the son has a larger one [63]. The extent of spermatogenic failure (still in the range of azoo-/oligozoospermia) cannot be predicted entirely in the son, due to the different genetic background and the presence or absence of environmental factors with potential toxicity for reproductive function. A significant proportion of spermatozoa from men with complete AZFc deletion are nullisomic for sex chromosomes [64, 65], indicating a potential risk for any offspring to develop 45,X0 Turner's syndrome and other phenotypic anomalies associated with sex chromosome mosaicism, including ambiguous genitalia [66]. Despite this theoretical risk, babies born from fathers affected by Yq microdeletions are phenotypically normal [58, 67]. This could be due to the reduced implantation rate and a likely higher risk of spontaneous abortion of embryos bearing a 45,X0 karyotype. When ICSI is used in the presence of a Y microdeletion, long-term follow-up of any male children is needed with respect to their fertility status, and cryopreservation of spermatozoa at a young age can be considered.

3C.3.1.3 Y-chromosome: 'gr/gr' deletion

A new type of Yq deletion, known as the gr/gr deletion, has been described in the AZFc region [68]. This deletion removes half of the gene content of the AZFc region, affecting the dosage of multicopy genes mapping inside this region. This type of deletion confers a 2.5-8 fold increased risk for oligozoospermia [62, 69-71]. The frequency of gr/gr deletion in oligozoospermic patients is ~4%.

According to four meta-analyses, gr/gr deletion is a significant risk factor for impaired sperm production [70, 71]. It is worth noting that both the frequency of gr/gr deletion and its phenotypic expression vary between different ethnic groups, depending on the Y-chromosome background. For example, in some Y haplogroups, the deletion is fixed and appears to have no negative effect on spermatogenesis. Consequently, the routine screening for gr/gr deletion is still a debated issue, especially in those laboratories serving diverse ethnic and geographic populations. A large multicentre study has shown that gr/gr deletion is a potential risk factor for testicular germ cell tumours [72]. However, these data need further confirmation in an ethnically and geographically matched case-control study setting. For genetic counselling it is worth noticing that partial AZFc deletions (gr/gr and b2/b3) may predispose to complete AZFc deletion in the next generation [73].

3C.3.1.4 Autosomal defects with severe phenotypic abnormalities and infertility

Several inherited disorders are associated with severe or considerable generalised abnormalities and infertility. Among them, Prader-Willy Syndrome, Bardet-Biedl Syndrome, Noonan's Syndrome, Myotonic dystrophy, dominant polycystic kidney disease, 5 α -reductase deficiency, etc. Patients with these defects will be well known to doctors, often from childhood. A fertility problem must be managed in the context of the care of the man as a whole and considering the couple's ability to care for a child.

3C.4 Cystic fibrosis mutations and male infertility

Cystic fibrosis (CF) is a fatal autosomal-recessive disorder. It is the most common genetic disease of Caucasians; 4% are carriers of gene mutations involving the CF transmembrane conductance regulator (CFTR) gene located on chromosome 7p. It encodes a membrane protein that functions as an ion channel and influences the formation of the ejaculatory duct, seminal vesicle, vas deferens and distal two-thirds of the epididymis.

Congenital bilateral absence of the vas deferens (CBAVD) is associated with CFTR gene mutations and was found in ~2% of men with OA attending a clinic in Edinburgh, UK [74]. The incidence in men with OA varies between different countries. The clinical diagnosis of absent vasa is easy to miss and all men with azoospermia should be very carefully examined to exclude CBAVD, particularly those with a semen volume < 1.5 mL and pH < 7.0. Approximately 1,500 mutations are listed on the CFTR database (<http://www.geneticsickkids.on.ca/cftr/>). The most frequently found mutations are the F508, R117H and W1282X, but their frequency and the presence of other mutations largely depend on the ethnicity of the patient [75, 76]. Given the functional relevance of a DNA variant (the 5T allele) in a non-coding region of CFTR [75], it is now considered a mild CFTR mutation

rather than a polymorphism and it should be analysed in each CAVD patient. As more mutations are defined and tested for, almost all men with CBAVD will probably be found to have mutations. It is not practical to test for all known mutations, because many have a very low prevalence in a particular population. Routine testing is usually restricted to the most common mutations in a particular community through the analysis of a mutation panel. Given that this is a recessive disease if a second mutation is not found with the routine panel, a second step analysis is advised which comprises the direct sequencing of the entire gene. Men with CBAVD often have mild clinical stigmata of CF (e.g., history of chest infections). When a man has CBAVD, it is important to test also his partner for CF mutations. If the female partner is found to be a carrier of CFTR mutations, the couple must consider very carefully whether to proceed with ICSI using the male's sperm, as the risk of having a child with CF or CBAVD will be 50%, depending on the type of mutations carried by the parents. If the female partner is negative for known mutations, the risk of being a carrier of unknown mutations is ~0.4%.

3C.4.1 Unilateral or bilateral absence/abnormality of the vas and renal anomalies

Unilateral absence of the vas deferens is usually associated with ipsilateral absence of the kidney and probably has a different genetic causation [77]. Consequently, in these subjects CFTR mutation screening is not indicated. Men with unilateral absence of the vas deferens are usually fertile, and the condition is most commonly encountered as an incidental finding in the vasectomy clinic. CFTR gene mutation screening is indicated in men with unilateral absence of the vas deferens with normal kidneys.

An abdominal ultrasound should be undertaken both in unilateral and bilateral absence of vas deferens. Findings may range from unilateral absence of the vas with ipsilateral absence of the kidney, to bilateral vessel abnormalities and renal abnormalities, such as pelvic kidney [78].

3C.4.2 Unknown genetic disorders

Considering the high predicted number of genes involved in male gametogenesis, it is likely that most idiopathic forms of spermatogenic disturbances are caused by mutations or polymorphisms in spermatogenesis candidate genes [53]. However, despite an intensive search for new genetic factors, no clinically relevant gene mutations or polymorphisms (except those related to the Y-chromosome) have so far been identified [53, 79, 80], and references therein. The introduction of new analytical approaches provided evidence for the importance of CNVs [55, 56] and further advances are expected with Next Generation Sequencing. Intracytoplasmic sperm injection is used to enable men with severely damaged spermatogenesis to father children in situations formerly considered hopeless and where very few spermatozoa can be obtained. This has led to concern that children may be born with a foetal abnormality, because ICSI may enable defective sperm to bypass the selective processes of the female genital tract and egg covering.

Intracytoplasmic sperm injection babies have a higher risk of de novo sex chromosomal aberrations (about a threefold increase compared with natural conceptions) and paternally inherited structural abnormalities. Treatment with assisted reproductive technology was associated with increased risk of cardiovascular, musculoskeletal, urogenital, and gastrointestinal defects and cerebral palsy [81-83].

3C.4.3 DNA fragmentation in spermatozoa

There is increased DNA damage in spermatozoa from men with oligozoospermia. This increase is associated with reduced chances of natural conception and an increased chance of early pregnancy loss [84].

3C.4.4 Genetic counselling and ICSI

Initially, the couple should be given full information about the risks to the child in order to help them decide whether to proceed with ICSI. Where there is conflict between the wishes of the couple and the interests of the future child, it may be ethically correct to withhold therapy. When both partners are known to carry defects (e.g., CFTR mutations), there is up to a 50% chance of the child developing a clinical condition. Many clinicians and infertility clinic personnel may consider it unethical to proceed because their duty of care to the future child and the interests of society outweigh the wishes of the individual couple. If there is a conflict that cannot be resolved by agreement, the interests of a future child probably take precedence over the interests of a couple. The couple also need to give consideration to preimplantation diagnosis.

3C.5 Conclusions and recommendations for genetic disorders in male infertility

Conclusions	LE
New insights into the genetic basis of infertility and the advent of ICSI require a good understanding of genetics by clinicians and the general public.	3
Diagnostic advances will allow us to identify the genetic basis of more disorders and diagnose known disorders at a lower cost. For some of these disorders, gene therapy might be practical in the future.	2a
In men with spermatogenic damage there is a higher prevalence of chromosome abnormalities reaching the highest frequency in NOA men.	1b
AZF deletions are clear-cut causes of spermatogenic impairments with diagnostic and prognostic value for TESE.	1a
AZF deletion will be obligatorily transmitted to the son.	1a
gr/gr deletion has been confirmed as a significant risk factor for impaired sperm production, whereas further evidence of the prognostic significance of gr/gr and development of a testicular germ cell tumour is needed.	2b

Recommendations	GR
From a diagnostic view point, standard karyotype analysis should be offered to all men with damaged spermatogenesis (spermatozoa < 10 million/mL) who are seeking fertility treatment by IVF.	B
Genetic counselling is mandatory in couples with a genetic abnormality found in clinical or genetic investigation and in patients who carry a (potential) inheritable disease.	A
All men with Klinefelter's syndrome need long-term endocrine follow-up and usually require androgen replacement therapy.	A
Testing for microdeletions is not necessary in men with OA (with normal FSH) when ICSI is used because spermatogenesis should be normal.	A
Men with severely damaged spermatogenesis (spermatozoa < 5 million/mL) should be advised to undergo Yq microdeletion testing for both diagnostic and prognostic purposes. Yq microdeletion also has important implications for genetic counselling.	A
If complete AZFa or AZFb microdeletions are detected, micro-TESE should not be performed because it is extremely unlikely that any sperm will be found.	A
If a man with Yq microdeletion and his partner wish to proceed with ICSI, they should be advised that microdeletions will be passed to sons, but not to daughters.	A
When a man has structural abnormalities of the vas deferens (unilateral or bilateral absence), he and his partner should be tested for CF gene mutations.	A

IVF = *in vitro* fertilisation; OA = obstructive azoospermia; FSH = follicle-stimulating hormone; ICSI = intracytoplasmic sperm injection; TESE = testicular sperm extraction; CF = cystic fibrosis.

3D OBSTRUCTIVE AZOOSPERMIA

Obstructive azoospermia (OA) is the absence of spermatozoa and spermatogenic cells in semen and post-ejaculate urine due to obstruction. OA is less common than NOA and occurs in 15-20% of men with azoospermia. Men with OA present with normal FSH, normal size testes, and epididymal enlargement. Sometimes, the vas deferens is absent. Obstruction in primary infertile men is often present at the epididymal level.

3D.1 Classification

3D.1.1 Intratesticular obstruction

Intratesticular obstruction occurs in 15% of men with OA [85]. Congenital forms are less common than acquired forms (post-inflammatory or post-traumatic).

3D.1.2 Epididymal obstruction

Epididymal obstruction is the most common cause of OA, affecting 30-67% of azoospermic men [85-88]. Congenital epididymal obstruction usually manifests as CBAVD, which is associated with at least one mutation of the CF gene in 82% of cases [89]. Congenital forms of epididymal obstruction include chronic

sinopulmonary infections (Young's syndrome) [90]. Acquired forms secondary to acute (e.g., gonococcal) and subclinical (e.g., chlamydial) epididymitis are most common [91, 92]. Other causes may be trauma or surgical intervention [93, 94].

3D.1.3 Vas deferens obstruction

Vas deferens obstruction is the most common cause of acquired obstruction following vasectomy [95]. Approximately 2-6% of these men request vasectomy reversal (see Chapter 3G). Vasal obstruction may also occur after hernia repair [96, 97]. The most common congenital vasal obstruction is CBAVD, often accompanied by CF. Unilateral agenesis or a partial defect is associated with contralateral seminal duct anomalies or renal agenesis in 80% and 26% of cases, respectively [98] (see Chapter 3C).

3D.1.4 Ejaculatory duct obstruction

Ejaculatory duct obstruction is found in 1-3% of cases of OA [85] and is classified as either cystic or post-inflammatory. Cystic obstructions are usually congenital (i.e., Mullerian duct cyst or urogenital sinus/ejaculatory duct cysts) and are typically midline. In urogenital sinus abnormalities, one or both ejaculatory ducts empty into the cyst [99], while in Mullerian duct anomalies, the ejaculatory ducts are laterally displaced and compressed by the cyst [100]. Paramedian or lateral intraprostatic cysts are rare [101]. Post-inflammatory obstructions of the ejaculatory duct are usually secondary to urethroprostatitis [102]. Congenital or acquired complete obstructions of the ejaculatory ducts are commonly associated with low semen volume, decreased or absent seminal fructose, and acid pH. The seminal vesicles are usually dilated (anterior-posterior diameter > 15 mm) [102, 103].

3D.1.5 Functional obstruction of the distal seminal ducts

Functional obstruction of the distal seminal ducts might be attributed to local neuropathy [104]. This abnormality is often associated with urodynamic dysfunction. Impaired sperm transport may be idiopathic or associated with SSRI medication as well.

3D.2 Diagnostic evaluation

3D.2.1 Clinical history

Clinical history taking should follow the suggestions for the diagnostic evaluation of infertile men (3A.2).

3D.2.2 Clinical examination

Clinical examination should follow suggestions for the diagnostic evaluation of infertile men. The following findings indicate OA:

- At least one testis with a volume > 15 mL, although a smaller volume may be found in some patients with OA and concomitant partial testicular failure.
- Enlarged and hardened epididymis.
- Nodules in the epididymis or vas deferens.
- Absence or partial atresia of the vas.

3D.2.3 Semen analysis

At least two examinations must be carried out at an interval of 2-3 months, according to the WHO (see Chapter 3A.2). Azoospermia means the inability to detect spermatozoa after centrifugation at $\times 400$ magnification. When semen volume is low, a search must be made for spermatozoa in urine after ejaculation. Absence of spermatozoa and immature germ cells in semen smears suggest complete seminal duct obstruction.

3D.2.4 Hormone levels

Serum FSH levels may be normal, but do not exclude a testicular cause of azoospermia. FSH level is normal in 40% of men with primary spermatogenic failure. Inhibin B seems to have a higher predictive value for normal spermatogenesis [88].

3D.2.5 Ultrasonography

In addition to physical examination, a scrotal ultrasound may be helpful in finding signs of obstruction (e.g., dilatation of rete testis, enlarged epididymis with cystic lesions, or absent vas deferens) and may demonstrate signs of testicular dysgenesis (e.g., non-homogeneous testicular architecture and microcalcifications) and associated ITGCN. For patients with a low seminal volume and in whom distal obstruction is suspected, transrectal ultrasound (TRUS) is essential. Invasive diagnosis, including testicular biopsy, scrotal exploration, and distal seminal duct evaluation, are indicated in patients with OA in whom an acquired obstruction of the seminal ducts is suspected. Explorative and recanalisation surgery should be carried out simultaneously.

3D.2.6 **Testicular biopsy**

In selected cases, testicular biopsy may be indicated to exclude spermatogenic failure. Testicular biopsy should be combined with extraction of testicular spermatozoa (i.e., TESE) for cryopreservation.

3D.3 **Disease management**

3D.3.1 **Intratesticular obstruction**

Only TESE allows sperm retrieval in these patients and is therefore recommended.

3D.3.2 **Epididymal obstruction**

Microsurgical epididymal sperm aspiration (MESA) [105] is indicated in men with CBAVD. TESE and PESA are also viable options [106]. Usually, one MESA procedure provides sufficient material for several ICSI cycles [107] and it produces high pregnancy and fertilisation rates [108]. In patients with azoospermia due to acquired epididymal obstruction, microsurgical reconstruction is recommended, with the preferred technique being microsurgical intussusception tubulovasectomy [109]. Reconstruction may be carried out unilaterally or bilaterally; patency and pregnancy rates are usually higher with bilateral reconstruction. Anatomical recanalisation following surgery may require 3-18 months. Before microsurgery (and in all cases where recanalisation is impossible), epididymal spermatozoa should be aspirated and cryopreserved for use in ICSI [107]. Patency rates range between 60% and 87% [94, 110] and cumulative pregnancy rates between 10% and 43%. Recanalisation success rates may be adversely affected by preoperative and intraoperative findings.

3D.3.3 **Proximal vas obstruction**

Proximal vas obstruction after vasectomy requires microsurgical vasectomy reversal (see Chapter 3G). Vasovasostomy is also required in rare cases of proximal vasal obstructions. The absence of spermatozoa in the intraoperative vas deferens fluid suggests the presence of a secondary epididymal obstruction; especially if the seminal fluid of the proximal vas has a thick “toothpaste” appearance. Microsurgical tubulovasostomy is then indicated.

3D.3.4 **Distal vas deferens obstruction**

It is usually impossible to correct large bilateral vas deferens defects, resulting from involuntary excision of the vasa deferentia during hernia surgery in early childhood or previous orchidopexy [111]. In these cases TESE/ MESA or proximal vas deferens sperm aspiration [112] can be used for cryopreservation for future ICSI.

3D.3.5 **Ejaculatory duct obstruction**

The treatment of ejaculatory duct obstruction depends on its aetiology. Transurethral resection of the ejaculatory ducts (TURED) [102] can be used in large postinflammatory obstruction and when one or both ejaculatory ducts empty into an intraprostatic midline cyst. Resection may remove part of the verumontanum. In cases of obstruction due to a midline intraprostatic cyst, incision or unroofing of the cyst is required [102]. Intraoperative TRUS makes this procedure safer. If distal seminal tract evaluation is carried out at the time of the procedure, installation of methylene blue dye into the vas deferens can help to document opening of the ducts. The limited success rate of surgical treatment of ejaculatory duct obstruction in terms of spontaneous pregnancies should be weighed against sperm aspiration and ICSI. Complications following TURED include retrograde ejaculation due to bladder neck injury and urine reflux into the ejaculatory ducts, seminal vesicles, and vasa. The alternatives to TURED are MESA, TESE, proximal vas deferens sperm aspiration, seminal vesicle ultrasonically guided aspiration, and direct cyst aspiration. Spermatozoa can then be retrieved by antegrade seminal tract washout [113].

3D.4 **Conclusions and recommendation for obstructive azoospermia**

Conclusions	LE
Obstructive lesions of the seminal tract should be suspected in azoospermic or severely oligozoospermic patients with normal-sized testes and normal endocrine parameters.	3

Recommendations	GR
In azoospermia caused by epididymal obstruction, standard procedures include vasovasostomy and tubulovastomy.	B
Sperm retrieval techniques, such as MESA, TESE, and PESA, can be used additionally. These methods should be used only when cryostorage of the material obtained is available.	B
In azoospermia caused by epididymal obstruction, scrotal exploration with microsurgical epididymal sperm aspiration and cryopreservation of spermatozoa should be performed. Microsurgical reconstruction should be performed, if applicable. Results of reconstructive microsurgery depend on the cause and location of the obstruction, and the surgeon's expertise.	B

3E VARICOCELE

Varicocele is a common abnormality which may be associated with the following andrological conditions:

- Failure of ipsilateral testicular growth and development.
- Symptoms of pain and discomfort.
- Male subfertility.
- Hypogonadism.

3E.1 Classification

The following classification of varicocele [114] is useful in clinical practice:

- Subclinical: not palpable or visible at rest or during Valsava manoeuvre, but can be shown by special tests (Doppler ultrasound studies).
- Grade 1: palpable during Valsava manoeuvre, but not otherwise.
- Grade 2: palpable at rest, but not visible.
- Grade 3: visible and palpable at rest.

3E.2 Diagnostic evaluation

The diagnosis of varicocele is made by clinical examination and should be confirmed by colour Duplex analysis [10]. In centres where treatment is carried out by antegrade or retrograde sclerotherapy or embolisation, diagnosis is additionally confirmed by X-ray.

3E.3 Basic considerations

3E.3.1 *Varicocele and fertility*

Varicocele is a physical abnormality present in 11.7% of adult men and in 25.4% of men with abnormal semen analysis [115]. The exact association between reduced male fertility and varicocele is unknown, but a recent meta-analysis showed that semen improvement is usually observed after surgical correction [116]. Varicocelectomy can reverse sperm DNA damage [117].

3E.3.2 *Varicocelectomy*

Varicocele repair has been a subject of debate for several decades. The 2009 Cochrane review concluded that there is no evidence that treatment of varicocele improves a couples' chance of conception [118]. In a recent meta-analysis of four RCTs of varicocelectomy in men with a clinical varicocele, oligozoospermia and otherwise unexplained infertility, there was a trend in favour of surgical correction [119]. Although treatment of varicocele in infertile men may be effective, in adolescents there is a significant risk of overtreatment: most adolescents with a varicocele will have no problem achieving pregnancy later in life [120].

3E.4 Disease management

Several treatments are available for varicocele (Table 4). Current evidence indicates that microsurgical varicocelectomy is the most effective and least morbid method among the varicocelectomy techniques [120].

Table 4: Recurrence and complication rates associated with treatments for varicocele

Treatment	Ref.	Recurrence/ persistence %	Complication rates
Antegrade sclerotherapy	[121]	9	Complication rate 0.3-2.2%: testicular atrophy, scrotal haematoma, epididymitis, left-flank erythema
Retrograde sclerotherapy	[122]	9.8	Adverse reaction to contrast medium, flank pain, persistent thrombophlebitis, vascular perforation
Retrograde embolisation	[123, 124]	3.8-10	Pain due to thrombophlebitis, bleeding haematoma, infection, venous perforation, hydrocele, radiological complication (e.g., reaction to contrast media), misplacement or migration of coils, retroperitoneal haemorrhage, fibrosis, ureteric obstruction
<i>Open operation</i>			
Scrotal operation		-	Testicular atrophy, arterial damage with risk of devascularisation and testicular gangrene, scrotal haematoma, postoperative hydrocele
Inguinal approach	[125]	13.3	Possibility of missing out a branch of testicular vein
High ligation	[126]	29	5-10% incidence of hydrocele (< 1%)
Microsurgical inguinal or subinguinal	[127, 128]	0.8-4	Postoperative hydrocele arterial injury, scrotal haematoma
Laparoscopy	[129, 130]	3-7	Injury to testicular artery and lymph vessels; intestinal, vascular and nerve damage; pulmonary embolism; peritonitis; bleeding; postoperative pain in right shoulder (due to diaphragmatic stretching during pneumoperitoneum); pneumoscrotum: wound infection

3E.5 Conclusions and recommendations for varicocele

Conclusions	LE
Current information supports the hypothesis that the presence of varicocele in some men is associated with progressive testicular damage from adolescence onwards and a consequent reduction in fertility.	2a
Although the treatment of varicocele in adolescents may be effective, there is a significant risk of overtreatment.	3
Varicocele repair may be effective in men with subnormal semen analysis, a clinical varicocele and otherwise unexplained infertility.	1a

Recommendations	GR
Varicocele treatment is recommended for adolescents with progressive failure of testicular development documented by serial clinical examination.	B
No evidence indicates benefit from varicocele treatment in infertile men who have normal semen analysis or in men with subclinical varicocele. In this situation, varicocele treatment cannot be recommended.	A
Varicocele repair should be considered in case of a clinical varicocele, oligospermia, infertility duration of ≥ 2 years and otherwise unexplained infertility in the couple.	A

3F HYPOGONADISM

Hypogonadism is characterised by impaired testicular function, which may affect spermatogenesis and/or testosterone synthesis. The symptoms of hypogonadism depend on the degree of androgen deficiency and if the condition develops before or after pubertal development of the secondary sex characteristics.

3F.1 Epidemiology and aetiology

The aetiological and pathogenetic mechanisms of male hypogonadism can be divided into three main categories:

1. Primary (hypergonadotrophic) hypogonadism due to testicular failure.
2. Secondary (hypogonadotrophic) hypogonadism caused by insufficient gonadotropin-releasing hormone (GnRH) and/or gonadotropin (FSH, LH) secretion.
3. Androgen insensitivity (end-organ resistance).

The most common conditions within these three categories are given in Table 5 (see also Chapter 3C).

Table 5: Disorders associated with male hypogonadism*

Primary (hypergonadotrophic) hypogonadism (testicular failure)*
Anorchia
Maldescended testes
Klinefelter's syndrome
Y-chromosome microdeletions
Numerical and structural chromosomal anomalies
Trauma, testicular torsion, orchitis
Iatrogenic (surgery, medications, irradiation, or cytostatic drugs)
Exogenous factors (toxins, heat, or occupational hazards)
Systemic diseases (liver cirrhosis, or renal failure)
Testicular tumour
Varicocele
Idiopathic (e.g., late-onset hypogonadism)
Secondary (hypogonadotrophic) hypogonadism (secondary testicular failure)
Congenital
Idiopathic hypogonadotrophic hypogonadism
Normosmic
Hiposmic/anosmic (Kallmann syndrome)
Acquired (tumours in the following regions)
Diencephalon (craniopharyngioma or meningioma)
Hypothalamus or pituitary
Empty sella syndrome
Granulomatous illnesses
Fractures of the skull base
Ischaemic or haemorrhagic lesions in hypothalamic area
Hyperprolactinaemia
Drugs/anabolic steroids, radiotherapy
Target organ resistance to androgens
Testicular feminisation
Reifenstein syndrome

*Modified from Nieschlag et al. [6].

3F.2 Idiopathic hypogonadotrophic hypogonadism: aetiology, diagnosis and therapeutic management

Idiopathic hypogonadotrophic hypogonadism is characterised by low levels of gonadotropins and sex steroid in the absence of anatomical or functional abnormalities of the hypothalamic-pituitary-gonadal axis [131]. Idiopathic hypogonadotrophic hypogonadism may be an isolated condition or may be associated with anosmia/hyposmia (Kallmann syndrome). Genetic factors causing a deficit of gonadotropins may act at the hypothalamic or pituitary level. Mutations in candidate genes (X-linked or autosomal) can be found in ~30% of congenital cases [131] and should be screened prior to assisted reproduction [132]. Acquired

hypogonadotrophic hypogonadism can be caused by some drugs, hormones, anabolic steroids, or tumours. A suspected tumour requires imaging [computed tomography (CT) or magnetic resonance imaging (MRI)] of the sella region and a complete endocrine work-up. Normal androgen levels and subsequent development of secondary sex characteristics (in cases of onset of hypogonadism before puberty) and a eugonadal state can be achieved by androgen replacement alone. However, stimulation of sperm production requires treatment with human chorionic gonadotropin (hCG) combined with recombinant FSH or urinary FSH or human menopausal gonadotropins (HMGs). If hypogonadotrophic hypogonadism is hypothalamic in origin, an alternative to hCG treatment is pulsatile GnRH [133]. In patients who have developed hypogonadism before puberty and have not been treated with gonadotropins or GnRH, 1-2 years of therapy may be needed to achieve sperm production.

3F.3 Hypergonadotrophic hypogonadism: aetiology, diagnosis and therapeutic management

Many conditions in men are associated with hypergonadotrophic hypogonadism (Table 6, see also Chapter 3C). Most conditions listed in Table 6 only affect the reproductive function of the testes so that only FSH level is elevated. However, it has been reported that men with infertility are at higher risk for developing impaired Leydig cell function [134], while men with Klinefelter's syndrome often show high LH values and develop hypoandrogenism with ageing [135]. A decrease in testosterone blood concentrations after extensive testicular biopsy in the context of TESE/ICSI has been observed, raising questions about the need for long-term endocrine follow-up of these patients [136]. Laboratory diagnosis of hypergonadotrophic hypogonadism is based on a high level of FSH, decreased serum testosterone, and increased LH levels [132]. Testosterone levels should be evaluated in view of the serum concentration of sex hormone binding globulin (SHBG). Based on levels of total testosterone, albumin and SHBG, free and bioavailable testosterone can be calculated. Due to diurnal variation, blood samples for testosterone assessment should be taken before 10.00 am. Generally, androgen replacement should not be given to men who are considering parenthood or in case of male infertility. Testosterone suppresses pituitary production of LH and FSH, therefore, replacement therapy should not be given for infertility. In obese men, low levels of testosterone may exist due to the conversion of testosterone in oestradiol by the enzyme aromatase [137]. Anti-oestrogens and aromatase inhibitors may help in these patients elevating FSH and LH and potentially increase sperm quality, next to weight reduction. Injectable, oral and transdermal testosterone preparations are available for clinical use [132]. See also EAU Guidelines on Male Hypogonadism [138].

3F.4 Conclusion and recommendations for hypogonadism

Conclusion	LE
Symptomatic patients with primary and secondary hypogonadism who are not considering parenthood are candidates for testosterone substitution therapy.	1b

Recommendations	GR
Effective drug therapy is available to achieve fertility in men with hypogonadotrophic hypogonadism [114].	A*
Testosterone replacement is strictly contraindicated for the treatment of male infertility (low levels of FSH and LH) [139].	A*

**Upgraded following panel consensus.*

FSH = follicle-stimulating hormone; LH = luteinising hormone.

3G CRYPTORCHIDISM

Cryptorchidism is the most common congenital abnormality of the male genitalia and is found in 2-5% of newborn boys, depending on gestational age (cryptorchidism occurs more often in premature boys) and age after birth. At the age of 3 months, the incidence of cryptorchidism falls spontaneously to 1-2%. Approximately 20% of undescended testes are non-palpable and may be located within the abdominal cavity.

3G.1 Aetiology and pathophysiology

The aetiology of cryptorchidism is multifactorial, involving disrupted endocrine regulation and several gene defects. It has been postulated that cryptorchidism may be a part of the so-called testicular dysgenesis syndrome (TDS), which is a developmental disorder of the gonads caused by environmental and/or genetic

influences early in pregnancy. Besides cryptorchidism, TDS includes hypospadias, reduced fertility, increased risk of malignancy, and Leydig cell dysfunction [140].

3G.1.1 Incidence of cryptorchidism

The Caucasian population has a threefold higher incidence of cryptorchidism compared to African-Americans. Premature babies have a much higher incidence of cryptorchidism than full-term babies. In a British study, the incidence of cryptorchidism was 2.7% in > 3,000 boys weighing > 2.5 Kg and 21% in premature boys weighing < 2.5 Kg. At the age of 3 months, spontaneous descent occurred in most boys, and the incidence of cryptorchidism fell to 0.9% and 1.7%, in the > 2.5 Kg and < 2.5 Kg group, respectively [141].

3G.1.2 Pathophysiological effects in maldescended testes

3G.1.2.1 Degeneration of germ cells

The degeneration of germ cells in maldescended testes is apparent after the first year of life. Degenerative changes vary, depending on the position of the testis [142]. During the second year, the number of germ cells declines. In 10-45% of affected patients, a complete loss of germ cells can be detected. Early treatment is therefore recommended to conserve spermatogenesis, especially in bilateral cases. Surgical treatment is the most effective and reliable method of bringing testes into the scrotum. Hormone treatment with hCG has been used widely in the past, but it has now been abolished because of increased germ cell apoptosis after treatment [143].

3G.1.2.2 Relationship with fertility

Semen parameters are often impaired in men with a history of cryptorchidism [144]. Surgical treatment during the first or second year of life may have a positive effect on subsequent fertility [145]. However, there is no definitive proof of the protective effect of early orchidopexy. In men with a history of unilateral cryptorchidism, paternity is almost equal (89.7%) to that in men without cryptorchidism (93.7%). In men with unilateral cryptorchidism, paternity is independent of age at orchidopexy and preoperative testicular location and size [146]. However, a history of unilateral cryptorchidism may result in reduced fertility potential and therefore a longer time to achieve pregnancy. In men with bilateral cryptorchidism, oligozoospermia can be found in 31% and azoospermia in 42%. In cases of bilateral cryptorchidism, the rate of paternity is only 35-53%. In cases of bilateral cryptorchidism and azoospermia, orchidopexy performed even in adult life might lead to the appearance of spermatozoa in the ejaculate [147].

3G.1.2.3 Germ cell tumours

Cryptorchidism is a risk factor for testicular cancer and is associated with testicular microcalcification and intratubular germ cell neoplasia of unclassified type (ITGCNU); formerly carcinoma *in situ* (CIS) of the testes. In 5-10% of testicular cancers, there is a history of cryptorchidism [148]. The risk of a germ cell tumour (GCT) is 3.6-7.4 times higher than in the general population and 2-6% of men with a history of cryptorchidism will develop a testicular tumour [148]. Orchidopexy performed before the age of puberty has been reported to decrease the risk of testicular cancer [149]. However, this and other similar reports are based on retrospective data and do not exclude the possibility that boys undergoing early and late orchidopexy represent different pathogenetic groups of testicular maldescent.

3G.2 Disease management

3G.2.1 Hormonal treatment

Human chorionic gonadotropin or GnRH has been used widely in the past to treat cryptorchidism in childhood. Although 15-20% of retained testes descend during hormonal treatment, one-fifth of these reascend later, which is why hormonal treatment is no longer recommended.

3G.2.2 Surgical treatment

The success rate of surgical treatment for undescended testes is 70-90% [150]. If the spermatic cords or the spermatic vessels are too short to allow proper mobilisation of the testis into the scrotum, a staged orchidopexy (Fowler-Stephenson procedure) can be performed, using open surgery, laparoscopy, or microsurgery. The optimal age for performing orchidopexy is still debated. Some retrospective studies have indicated that early treatment (during the first 2 years of life) has a beneficial effect on preserving future fertility [151], whereas a recent randomised study showed that surgery at 9 months resulted in a partial catch-up of testicular growth until at least age 4 years vs. surgery at 3 years [152]. The results clearly indicate that early surgery has a beneficial effect on testicular growth. Testicular volume is an approximate indirect measure of spermatogenic activity, therefore, it is possible that orchidopexy at an early age might improve future spermatogenesis.

In adulthood, undescended testis should not be removed because it still produces testosterone. Furthermore, as indicated above, correction of bilateral cryptorchidism, even in adulthood, can lead to sperm production in previously azoospermic men [147]. Vascular damage is the most severe complication of orchidopexy and can cause testicular atrophy in 1-2% of cases. In men with non-palpable testes, the postoperative atrophy rate was 12% in those cases with long vascular pedicles that enabled scrotal positioning. Postoperative atrophy in staged orchidopexy has been reported in up to 40% of patients [150].

3G.3 Conclusions and recommendations for cryptorchidism

Conclusions	LE
Cryptorchidism is multifactorial in origin and can be caused by genetic factors and endocrine disruption early in pregnancy.	3
Cryptorchidism is often associated with testicular dysgenesis and is a risk factor for infertility and GCT.	2b
Whether early surgical intervention can prevent germ cell loss is still debatable, but in a randomised study it improved testicular growth in boys treated at the age of 9 months compared to those aged years at the time of orchidopexy.	3
Paternity in men with unilateral cryptorchidism is almost equal to that in men without cryptorchidism.	3
Bilateral cryptorchidism significantly reduces the likelihood of paternity.	3

GCT = *germ cell tumour*.

Recommendations	GR
Hormonal treatment of cryptorchidism in adults is not recommended.	A
Early orchidopexy (6-12 months of age) might be beneficial for testicular development in adulthood.	B
If undescended testes are corrected in adulthood, testicular biopsy for detection of ITGCNU (formerly CIS) is recommended at the time of orchidopexy.	B

ITGCNU = *intratubular germ cell neoplasia of unclassified type*.

3H IDIOPATHIC MALE INFERTILITY

No demonstrable cause of infertility is found in at least 44% of infertile men [153].

3H.1 Disease management

3H.1.1 Empirical treatments

A wide variety of empirical drug treatments of idiopathic male infertility have been used. However, there is little scientific evidence for an empirical approach [154]. Clomiphen citrate and tamoxifen have been widely used in idiopathic OAT but there is no proven evidence for their benefit. A recent meta-analysis reported some improvement in sperm quality and spontaneous pregnancy rate [155]. Androgens, hCG/HMG, bromocriptine, alpha-blockers, systemic corticosteroids and magnesium supplementation are not effective in the treatment of OAT syndrome. Follicle-stimulating hormone might be beneficial in a selection of patients [155]. A Cochrane analysis showed that men taking oral antioxidants had an associated significant increase in live birth rate in IVF patients [156] when compared with men taking the control treatment. Concerning natural conception the role of antioxidants needs further investigations [157].

3H.2 Recommendation for idiopathic male infertility

Recommendation	GR
Medical treatment of male infertility is recommended only for cases of hypogonadotrophic hypogonadism.	A

31 MALE CONTRACEPTION

Development of male contraceptive methods is important because up to 40% of women have an unmet need for family planning, with approximately 80 million women every year having unintended or unwanted pregnancies [158]. Three of the four methods of male contraception have been in use for hundreds of years (i.e., condoms, periodic abstinence, and withdrawal). The typical first-year failure rates of traditional male methods are high (withdrawal 19%, periodic abstinence 20%, and condoms 3-14%) compared to the failure rates of 0.1-3% for modern reversible female methods [159]. For men, male contraceptive methods must be acceptable, cheap, reversible, and effective. The method nearest to being generally available clinically is hormonal male contraception, which is based on the suppression of gonadotropins and testosterone substitution to maintain male sexual function and bone mineralisation, and to prevent muscle wasting [160]. Various contraceptive regimens have been developed and tested, including testosterone monotherapy, androgen/progestin combinations, testosterone with GnRH analogues, and selective androgen- and progestin-receptor modulators. There are racial differences in the response to androgens alone. However, a combination of testosterone with progestin results in complete suppression of spermatogenesis in all races, and provides contraceptive efficacy equivalent to female hormonal methods [161].

31.1 Vasectomy

Vasectomy is an effective method of permanent male surgical sterilisation [162]. Extensive guidelines on vasectomy were published by the EAU in 2012 [2]. Before vasectomy, the couple should be fully informed about the benefits and risks, especially as an Australian telephone survey found that 9.2% of respondents regretted having a vasectomy [163].

31.1.1 Surgical techniques

Various techniques are available for vasectomy. The least invasive approach is no-scalpel vasectomy [164], which is also associated with a low rate of complications [165]. The most effective occlusion technique is cauterisation of the lumen of the vas deferens and fascial interposition [166-168]. Most techniques can be carried out safely under local anaesthesia in an outpatient clinic.

31.1.2 Complications

Vasectomy does not significantly alter spermatogenesis and Leydig cell function. The volume of ejaculate remains unchanged. Potential systemic effects of vasectomy, including atherosclerosis, have not been proven, and there is no evidence of a significant increase in any systemic disease after vasectomy. An increased rate of prostate cancer in men who underwent vasectomy has not been detected [162, 169]. Acute local complications associated with vasectomy include haematoma, wound infection, and epididymitis in up to 5% of cases [162]. The potential long-term complications (e.g., chronic testicular pain) [170] must be discussed with the patient before the procedure.

31.1.3 Vasectomy failure

If an effective occlusion technique is used, the risk of recanalisation after vasectomy should be < 1% [165]. However, patients should be informed preoperatively that, although rare, long-term recanalisation might occur [171]. No motile spermatozoa should be detected 3 months after vasectomy. Persistent motility is a sign of vasectomy failure, and the procedure will need to be repeated. A "special clearance" given by the urologist with non-motile spermatozoa < 100,000/mL is still under discussion [172].

31.1.4 Counselling

Counselling with regard to vasectomy must address the following aspects:

- Vasectomy should be considered irreversible.
- Vasectomy is associated with a low complication rate; however, because it is an elective operation, even small risks must be explained, because men (and their partners) might wish to consider these before giving consent.
- Vasectomy can fail, although the failure rate is low.
- Couples should be advised to continue with other effective contraception until clearance is confirmed.
- All available data indicate that vasectomy is not associated with any serious, long-term, side-effects [167].
- Vasectomy involving cauterisation and fascial interposition appears to be the most effective technique [165, 166, 168].

31.2 Vasectomy reversal

A wide range of surgical success rates have been published for vasectomy reversal (up to 90%), depending on the time between vasectomy and re-fertilisation, type of vasectomy (e.g., open-ended or sealed), type

of reversal (vasovasostomy or vasoepididymostomy), and whether reversal was unilateral or bilateral. Microsurgical techniques should be used [173].

31.2.1 **Length of time since vasectomy**

Vasovasostomy results have shown patency rates up to 90%. The longer the interval is from vasectomy to reversal, the lower is the pregnancy rate. In a study of 1,469 men who had undergone microsurgical vasectomy reversal, patency and pregnancy rates were 97% and 76%, respectively, for an interval up to 3 years after vasectomy; 88% and 53% for 3-8 years, 79% and 44% for 9-14 years, and 71% and 30% for > 15 years [174].

31.2.2 **Tubulovasostomy**

The chance of secondary epididymal obstruction after vasectomy increases with time. After an interval of 10 years, 25% of men appear to have epididymal blockage. If secondary epididymal obstruction occurs, tubulovasostomy is needed to reverse the vasectomy (see Chapter 3D) [109].

31.2.3 **Microsurgical vasectomy reversal vs. epididymal or testicular sperm retrieval and ICSI**

According to the calculations of cost per delivery for vasectomy reversal vs. sperm retrieval/ICSI, under a wide variety of initial assumptions, it is clear that vasectomy reversal is associated with a considerably lower cost per delivery and higher delivery rates [106, 175-177]. Sperm retrieval and ICSI must yield an 81% pregnancy rate per cycle to achieve equal costs to vasectomy reversal.

31.3 **Conclusions and recommendations for male contraception**

Conclusions	LE
Vasectomy is considered the gold standard for the male contribution to contraception.	1
All available data indicate that vasectomy is not associated with any serious, long-term side-effects.	1b
Pregnancy is still achievable after successful vasectomy reversal.	2a
Methods of male contraception other than vasectomy are associated with high failure rates or are still experimental (e.g., hormonal approach).	3

Recommendations	GR
Vasectomy meets best the criteria for the male contribution to contraception, with regard to efficacy, safety and side effects. Cauterisation and fascial interposition are the most effective techniques.	A
Patients seeking consultation about vasectomy must be informed about the surgical method, risk of failure, irreversibility, the need for post-procedure contraception until clearance, and the risk of complications.	A*
Microsurgical vasectomy reversal is a low-risk and (cost-) effective method of restoring fertility.	B
MESA/PESA/TESE and ICSI should be reserved for failed vasectomy reversal surgery.	A
For couples wanting to achieve pregnancy, sperm aspiration together with ICSI is a second-line option for selected cases and those with failed vasovasostomy.	B

*Upgraded following panel consensus

MESA = microsurgical epididymal sperm aspiration; PESA = percutaneous epididymal sperm aspiration; TESE = testicular sperm extraction; ICSI = intracytoplasmic sperm injection.

3J **MALE ACCESSORY GLAND INFECTIONS AND INFERTILITY**

Infections of the male urogenital tract are potentially curable causes of male infertility [10, 178, 179]. The WHO considers urethritis, prostatitis, orchitis and epididymitis to be male accessory gland infections (MAGIs) [10]. However, specific data are not available to confirm that these diseases have a negative influence on sperm quality and male fertility in general.

3J.2 Diagnostic evaluation

3J.2.1 Ejaculate analysis

Ejaculate analysis (see Chapter 3A.2) clarifies whether the prostate is involved as part of a generalised MAGI and provides information about sperm quality. In addition, leukocyte analysis allows differentiation between inflammatory and non-inflammatory chronic pelvic pain syndrome (CPPS) (NIH IIa vs. NIH 3B).

3J.2.1.1 Microbiological findings

After exclusion of urethritis and bladder infection, >10⁶ peroxidase-positive white blood cells (WBCs) per millilitre of ejaculate indicate an inflammatory process. In this case, a culture should be performed for common urinary tract pathogens. A concentration of >10³ cfu/mL urinary tract pathogens in the ejaculate is indicative of significant bacteriospermia. The sampling time can influence the positive rate of microorganisms in semen and the frequency of isolation of different strains [180]. The ideal diagnostic test for *Chlamydia trachomatis* in semen has not yet been established [181]. In contrast to serological findings in women, antibody tests for *C. trachomatis* in seminal plasma are not indicative if no type-specific methods are used [181].

Ureaplasma urealyticum is pathogenic only in high concentrations (>10³ cfu/mL ejaculate). No more than 10% of samples analysed for ureaplasma exceed this concentration [182]. Normal colonisation of the urethra hampers the clarification of mycoplasma-associated urogenital infections, using samples such as the ejaculate [183].

3J.2.1.2 White blood cells

The clinical significance of an increased concentration of leukocytes in the ejaculate is controversial [184]. Infection is indicated only by an increased level of leukocytes. Although leukocytospermia is a sign of inflammation, it is not necessarily associated with bacterial or viral infections [185]. According to WHO classification, leukocytospermia is defined as >10⁶ WBCs/mL. Only two studies have analysed alterations of WBCs in the ejaculate of patients with proven prostatitis [186, 187]. Both studies found more leukocytes in men with prostatitis compared to those without inflammation (CPPS, type NIH 3B).

3J.2.1.3 Sperm quality

The deleterious effects of chronic prostatitis on sperm density, motility and morphology are under debate [179]. All investigations have given contradictory results, and have not confirmed that chronic prostatitis has a decisive role in altering conventional semen parameters [188-190].

3J.2.1.4 Seminal plasma alterations

Seminal plasma elastase is a biochemical indicator of polymorphonuclear lymphocyte activity in the ejaculate [179, 191, 192], with a suggested cut-off level of approximately 600 ng/mL [179]. Various cytokines are involved in inflammation and can influence sperm function. Several studies have investigated the association between interleukin (IL) concentration, leukocytes, and sperm function [193-195], but no correlations have been found. The prostate is the main site of origin of IL-6 and IL-8 in the seminal plasma. Cytokines, especially IL-6, play an important role in the male accessory gland inflammatory process [196]. However, elevated cytokine levels do not depend on the number of leukocytes in expressed prostatic secretion (EPS) [197].

3J.2.1.5 Glandular secretory dysfunction

Infections of the sex glands can impair their excretory function. Decreased quantities of citric acid, phosphatase, fructose, zinc, and α -glutamyl-transferase activity are indicators of disturbed prostatic secretory parameters [179]. Reduced fructose concentration indicates impaired vesicular function [182, 198].

3J.2.1.6 Reactive oxygen species

Reactive oxygen species might be increased in chronic urogenital infections associated with increased leukocyte numbers [199]. However, their biological significance in prostatitis remains unclear [179].

3J.2.2 Disease management

Treatment of chronic prostatitis is usually targeted at relieving symptoms [200, 201]. The aims of therapy for altered semen composition in male adnexitis are:

- reduction or eradication of microorganisms in prostatic secretions and semen;
- normalisation of inflammatory (e.g., leukocytes) and secretory parameters;
- improvement of sperm parameters to counteract fertility impairment [202].

Only antibiotic therapy of chronic bacterial prostatitis (NIH II) has provided symptomatic relief, eradication of microorganisms, and a decrease in cellular and humoral inflammatory parameters in urogenital secretions.

Although antibiotics might improve sperm quality [202], there is no evidence that treatment of chronic prostatitis increases the probability of conception [179, 203].

3J.3 Epididymitis

Inflammation of the epididymis causes unilateral pain and swelling, usually with acute onset. Among sexually active men < 35 years of age, epididymitis is most often caused by *C. trachomatis* or *Neisseria gonorrhoea* [204, 205]. Sexually transmitted epididymitis is usually accompanied by urethritis. Non-sexually transmitted epididymitis is associated with urinary tract infection and occurs more often in men aged > 35 years [206].

3J.3.1 Diagnostic evaluation

3J.3.3.1 Ejaculate analysis

Ejaculate analysis according to WHO criteria, might indicate persistent inflammatory activity. Transiently decreased sperm counts and forward motility are observed [204, 207, 208]. Semen culture might help to identify pathogenic microorganisms. Development of stenosis in the epididymal duct, reduction of sperm count, and azoospermia are more important in the follow-up of bilateral epididymitis (see Chapter 3D).

3J.3.2 Disease management

Antibiotic therapy is indicated before culture results are available.

Treatment of epididymitis results in:

- microbiological cure of infection;
- improvement of clinical signs and symptoms;
- prevention of potential testicular damage;
- prevention of transmission;
- decrease of potential complications (e.g., infertility or chronic pain).

Patients with epididymitis known or suspected to be caused by *N. gonorrhoeae* or *C. trachomatis* must be told to refer their sexual partners for evaluation and treatment [209].

3J.4 Conclusions and recommendations for male accessory gland infections

Conclusions	LE
Urethritis and prostatitis are not clearly associated with male infertility.	3
Antibiotic treatment often only eradicates microorganisms; it has no positive effect on inflammatory alterations, and cannot reverse functional deficits and anatomical dysfunction.	2a
Although antibiotic treatment for MAGI might provide improvement in sperm quality, it does not necessarily enhance the probability of conception.	2a

Recommendation	GR
Patients with epididymitis that is known or suspected to be caused by <i>N. gonorrhoeae</i> or <i>C. trachomatis</i> must be instructed to refer their sexual partners for evaluation and treatment.	B

3K GERM CELL MALIGNANCY AND TESTICULAR MICROCALCIFICATION

3K.1 Germ cell malignancy and male infertility

Testicular germ cell tumour (TGCT) is the most common malignancy in Caucasian men aged 15-40 years, and affects approximately 1% of subfertile men. The lifetime risk of TGCT varies between ethnic groups and countries. The highest annual incidence of TGCT occurs in Caucasians, and varies from 10/100,000 (e.g., in Denmark and Norway) to 2/100,000 (e.g., in Finland and the Baltic countries). Generally, seminomas and non-seminomas are preceded by CIS, and untreated ITGCNU will eventually progress to invasive cancer [210, 211]. The most convincing evidence for a general decline in male reproductive health is the increase in testicular cancer seen in western countries [212]. In almost all countries with reliable cancer registers, the incidence of testicular cancer has increased [213]. Cryptorchidism and hypospadias are associated with an increased risk

of testicular cancer; men with cryptorchidism and/or hypospadias are over-represented among patients with testicular cancer. Men with dysgenic testes have an increased risk of developing testicular cancer in adulthood. These cancers arise from premalignant gonocytes or CIS cells [214]. Testicular microlithiasis (TM), seen on ultrasound, can be associated with GCT and CIS of the testes.

3K.2 Testicular germ cell cancer and reproductive function

Men with TGCT have decreased semen quality, even before cancer is diagnosed [215]. Orchidectomy implies a risk of azoospermia in these men, with sperm found in the ejaculate before the tumour-bearing testis has been removed. Semen cryopreservation before orchidectomy should therefore be considered (see Chapter 3M). Treatment of TGCT can result in additional impairment of semen quality [216]. In addition to spermatogenic failure, patients with TGCT have Leydig cell dysfunction, even in the contralateral testis [217].

The risk of hypogonadism may therefore be increased in men treated for TGCT. The measurement of pre-treatment levels of testosterone, SHBG, LH and oestradiol might help to anticipate post-treatment hypogonadism. Men who have had TGCT and have low normal androgen levels should receive long-term follow-up because they are at risk of developing hypogonadism as a result of an age-related decrease in testosterone production [218]. The risk of hypogonadism is most pronounced in TGCT patients treated with ≥ 3 cycles of chemotherapy or irradiation of retroperitoneal lymph nodes. However, this risk is greatest at 6-12 months post-treatment. This suggests there may be some improvement in Leydig cell function, and why it is reasonable to expect initiation of androgen replacement, until the patient shows continuous signs of testosterone deficiency, even at 2 years follow-up [219]. The risk of low libido and erectile dysfunction is also increased in TGCT patients [220]. In case of azoospermia, testicular sperm may be recovered to safeguard patient's fertility (Onco-TESE) [221].

3K.3 Testicular microlithiasis

Microcalcification inside the testicular parenchyma can be found in 0.6-9% of men referred for testicular ultrasound [222-225]. Although the true incidence of microcalcification in the general population is unknown, it is probably rare. However, ultrasound findings of TM are common in men with TGCT, cryptorchidism, testicular dysgenesis, infertility, testicular torsion and atrophy, Klinefelter's syndrome, hypogonadism, male pseudohermaphroditism, varicocele, epididymal cysts, pulmonary microlithiasis, and non-Hodgkin's lymphoma. The incidence reported seems to be higher with high-frequency ultrasound machines [226]. The relationship between TM and infertility is unclear, but probably relates to dysgenesis of the testes, with degenerate cells being sloughed inside an obstructed seminiferous tubule and failure of the Sertoli cells to phagocytose the debris. Subsequently, calcification occurs. Testicular microlithiasis is found in testes at risk of malignant development. The reported incidence of TM in men with TGCT is 6-46% [227-229]. TM should therefore be considered premalignant. Testicular biopsies from men with TM have found a higher prevalence of CIS, especially in those with bilateral microlithiasis [230]. However, TM is found most often in men with a benign testicular condition and the microcalcification itself is not malignant. Further investigation of the association between TM and CIS will require testicular biopsies in large series of men without signs of TGCT. However, available data indicate that men in whom TM is found by ultrasound, and who have an increased risk of TGCT, should be offered testicular biopsy for detection of CIS. The list of high-risk patients includes men with infertility and bilateral TM, atrophic testes, undescended testes, a history of TGCT, and contralateral TM [231].

3K.4 Recommendations for germ cell malignancy and testicular microcalcification

Recommendations	GR
As for all men, patients with TM and without special risk factors (see below) should be encouraged to perform self-examination because this might result in early detection of TGCT.	B
Testicular biopsy should be offered to men with TM, who belong to one of the following high-risk groups: infertility and bilateral TM, atrophic testes, undescended testes, a history of TGCT, or contralateral TM.	B
If there are suspicious findings on physical examination or ultrasound in patients with TM and associated lesions, surgical exploration with testicular biopsy or orchidectomy should be considered.	B
Testicular biopsy, follow-up scrotal ultrasound, routine use of biochemical tumour markers, or abdominal or pelvic CT, are not justified in men with isolated TM without associated risk factors (e.g. infertility, cryptorchidism, testicular cancer, and atrophic testis).	B
Men with TGCT are at increased risk of developing hypogonadism and sexual dysfunction and should therefore be followed up.	B

TM = testicular microlithiasis; TGCT = testicular germ cell tumour; CT = computed tomography.

3L DISORDERS OF EJACULATION

Disorders of ejaculation are uncommon, but important causes of male infertility.

3L.1 Classification and aetiology

3L.1.1 *Anejaculation*

Anejaculation involves complete absence of antegrade or retrograde ejaculation. It is caused by failure of semen emission from the seminal vesicles, prostate and ejaculatory ducts into the urethra [232]. True anejaculation is usually associated with a normal orgasmic sensation. True anejaculation is always associated with central or peripheral nervous system dysfunction or with drugs [233] (Table 6).

3L.1.2 *Anorgasmia*

Anorgasmia is the inability to reach orgasm and can give rise to anejaculation. Anorgasmia is often a primary condition and its cause is usually psychological.

3L.1.3 *Delayed ejaculation*

In delayed ejaculation, abnormal stimulation of the erect penis is needed to achieve orgasm with ejaculation [232]. Delayed ejaculation can be considered a mild form of anorgasmia. The causes of delayed ejaculation can be psychological, organic (e.g. incomplete spinal cord lesion [234] or iatrogenic penile nerve damage [235]), or pharmacological (e.g. selective serotonin re-uptake inhibitors (SSRIs), antihypertensives, or antipsychotics) [236].

3L.1.4 *Retrograde ejaculation*

Retrograde ejaculation is the total, or sometimes partial, absence of antegrade ejaculation as a result of semen passing backwards through the bladder neck into the bladder. Patients experience a normal or decreased orgasmic sensation. The causes of retrograde ejaculation can be divided into neurogenic, pharmacological, urethral, or bladder neck incompetence (Table 6).

Table 6: Aetiology of anejaculation and retrograde ejaculation

Neurogenic	Pharmacological
Spinal cord injury	Antihypertensives
Cauda equina lesions	α 1-adrenoceptor antagonists
Multiple sclerosis	Antipsychotics and antidepressants
Autonomic neuropathy (diabetes mellitus)	Alcohol
Retroperitoneal lymphadenectomy	
Sympathectomy or aortoiliac surgery	
Colorectal and anal surgery	
Parkinson's disease	
Urethral	Bladder neck incompetence
Ectopic ureterocele	Congenital defects/dysfunction of hemitrigone
Urethral stricture	Bladder extrophy
Urethral valves or verumontanum hyperplasia	Bladder neck resection (transurethral resection of the prostate)
Congenital dopamine β -hydroxylase deficiency	Prostatectomy

3L.1.5 *Asthenic ejaculation*

Asthenic ejaculation is characterised by an altered propulsive phase, with a normal emission phase [236]. The orgasmic sensation is reduced and the typically rhythmical contractions associated with ejaculation are missing. Asthenic ejaculation does not usually affect semen quality.

3L.1.6 *Premature ejaculation*

The International Society for Sexual Medicine (ISSM) has adopted the first evidence-based definition of lifelong premature ejaculation (PE): "Premature ejaculation is a male sexual dysfunction characterised by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy". Premature ejaculation may be strictly organic (e.g., prostatitis-related) or psychogenic, partner-related or non-selective, and can be associated with

erectile dysfunction. It does not impair fertility, provided intravaginal ejaculation occurs.

3L.2 Diagnostic evaluation

Diagnostic management includes the following recommended procedures.

3L.2.1 Clinical history

The patient must be carefully checked for diabetes, neuropathy, trauma, urogenital infection, previous surgery, and medication. Particular attention must be paid to the characteristics of micturition and ejaculation (presence of nocturnal emission, ejaculatory ability in given circumstances, and primary or acquired disorder), as well as to psychosexual aspects.

3L.2.2 Physical examination

Genital and rectal examinations are conducted, including evaluation of the prostate, bulbocavernosus reflex and anal sphincter tone.

3L.2.3 Post-ejaculatory urinalysis

Post-ejaculatory urinalysis of centrifuged urine can be used to determine if there is total or partial retrograde ejaculation.

3L.2.4 Microbiological examination

Initial, mid-stream urine, EPS, and/or urine after prostatic massage are cultured for evidence of prostatic infection. In cases of increased leukocytes in semen, semen culture or biochemical infection marker tests are also suggested [237].

3L.2.5 Optional diagnostic work-up

This diagnostic work-up can include:

- neurophysiological tests (bulbocavernosus evoked response and dorsal nerve somatosensory evoked potentials);
- tests for autonomic neuropathy;
- psychosexual evaluation;
- videocystometry;
- cystoscopy;
- transrectal ultrasonography;
- uroflowmetry;
- vibratory stimulation of the penis.

3L.3 Disease management

Infertility caused by disorders of ejaculation is seldom treated on the basis of aetiology. Treatment usually involves retrieval of spermatozoa for use in assisted reproduction techniques (ARTs). The following aspects must be considered when selecting treatment:

- Age of patient and his partner.
- Psychological problems of the patient and his partner.
- Couple's willingness and acceptance of different fertility procedures.
- Associated pathology.
- Psychosexual counselling.

3L.3.1 Aetiological treatment

If possible, any pharmacological treatment that is interfering with ejaculation should be stopped. In painful ejaculation, tamsulosin can be administered during antidepressant treatment [238]. Treatment should be given for urogenital infections (i.e., in case of painful ejaculation) [237]. Dapoxetine is an SSRI that has been introduced for the therapy of PE [239], because it appears that PE is related to serotonin levels. Psychotherapy is usually not very effective.

3L.3.2 Symptomatic treatment

3J.3.2.1 Premature ejaculation

Premature ejaculation can be treated with the SSRI dapoxetine or topical anaesthetic agents to increase intravaginal ejaculation latency time, behavioural therapy, and/or psychotherapy.

3L.3.2.2 Retrograde ejaculation

In the absence of spinal cord injury, anatomical anomalies of the urethra, or pharmacological agents, drug treatment must be used to induce antegrade ejaculation (Table 7). Alternatively, the patient can be encouraged to ejaculate when his bladder is full to increase bladder neck closure [240].

Table 7: Drug therapy for retrograde ejaculation

Drug	Dosage regimen	Ref.
Ephedrine sulphate	10-15 mg four times daily	[241]
Midodrine	5 mg three times daily	[242]
Brompheniramine maleate	8 mg twice daily	[243]
Imipramine	25-75 mg three times daily	[244]
Desipramine	50 mg every second day	[245]

Sperm collection from post-orgasmic urine for use in ART is recommended if:

- drug treatment is ineffective or intolerable as a result of side-effects;
- the patient has a spinal cord injury;
- drug therapy inducing retrograde ejaculation cannot be interrupted.

If the biological sperm preparation is not of sufficient quality for intrauterine insemination, the couple must undergo in vitro reproductive procedures (e.g. ICSI). In the case of insufficient drug therapy, testicular (TESE or PESA) or epididymal (MESA) sperm retrieval techniques can be used for assisted reproduction.

3L.3.2.3 Anejaculation

Drug treatment for anejaculation caused by lymphadenectomy and neuropathy, or psychosexual therapy for anorgasmia is not very effective. In all these cases, and in men who have a spinal cord injury, vibrostimulation (i.e., application of a vibrator to the penis) is first-line therapy. In anejaculation, vibrostimulation evokes the ejaculation reflex [246], which requires an intact lumbosacral spinal cord segment. If the quality of semen is poor, or ejaculation is retrograde, the couple may enter an IVF programme. If vibrostimulation has failed, electro-ejaculation can be the therapy of choice [247]. When electro-ejaculation fails or cannot be carried out, sperm can be retrieved from the seminal ducts by aspiration from the vas deferens [248] (see Chapter 3D) or seminal tract washout [249]. TESE can then be used [237, 250]. Anejaculation following either surgery for testicular cancer or total mesorectal excision can be prevented using monolateral lymphadenectomy or autonomic nerve preservation [250], respectively.

3L.4 Conclusion and recommendations for disorders of ejaculation

Conclusion	LE
Ejaculation disorders can be treated using a wide range of drugs and physical stimulation, with a high level of efficacy.	3

Recommendations	GR
Aetiological treatments for ejaculatory disorders should be offered before sperm collection and ART are performed.	B
Premature ejaculation can be treated successfully with either topical anaesthetic creams or SSRIs.	A
In men with spinal cord injury, vibrostimulation and electro-ejaculation are effective methods of sperm retrieval.	B

ART = assisted reproduction technique; SSRIs = selective serotonin reuptake inhibitors.

3M SEMEN CRYOPRESERVATION

Cryopreservation is the storage of biological material at subzero temperatures [e.g., -80 or -196°C (the boiling point of liquid nitrogen)], at which biochemical processes of cell metabolism are slowed or interrupted. At -196°C, the biochemical reactions that lead to cell death are stopped.

3M.1 Indications for storage

Storage of sperm is available in many clinics for the following indications:

- Before potentially sterilising chemotherapy or radiotherapy for cancer [251] or for non-malignant diseases.
- Before surgery that might interfere with fertility (e.g. bladder neck surgery in a younger man or removal of a testicle in a man with testicular malignancy, or before vasectomy or transgender surgery).
- For men with progressive decrease in semen quality as a result of diseases that have an associated risk of subsequent azoospermia (i.e., pituitary macroadenoma, craniopharyngioma, empty sella syndrome, chronic nephropathy, uncontrolled diabetes mellitus, and multiple sclerosis).
- For men with paraplegia when sperm have been obtained by electro-ejaculation or obtained by penile vibratory stimulation.
- For men with psychogenic anejaculation, after sperm have been obtained either by electro-ejaculation or a sperm retrieval procedure.
- After gonadotropin treatment has induced spermatogenesis in men with hypogonadotropic hypogonadism.
- For men with NOA, the chance of finding sperm using micro-TESE is ~50%.

Cryopreservation can be used for sperm collected through TESE, avoiding repeated sperm retrieval procedures and unnecessary hyperstimulation of the female partner.

- In any situation in which sperm have been obtained by a sperm retrieval procedure (e.g., after failed vasectomy reversal, or in some cases of epididymal obstruction not amenable to surgery).
- For storage of donor sperm, because cryopreservation reduces the risk of transmission of infection from sperm donors. According to the European directives 2004/23 EC and 2006/17 EC fresh sperm are no longer to be used for non-partner donations.

3M.2 Precautions and techniques

3M.2.1 *Freezing and thawing process*

The cryopreservation techniques currently used are not yet optimal because damage occurs to cells during cryopreservation and prolonged storage. Most damage occurs during freezing and thawing. Major causes of damage during freezing are ice crystal formation and cell dehydration, which disrupt the cell wall and intracellular organelles. Sperm morphology, motility and vitality decrease significantly after thawing, and cryopreservation increases the damage done to sperm DNA [252-255]. Further damage can be caused by contamination of samples with microorganisms and high levels of superoxide radicals [256, 257]. To reduce ice crystal formation, a cryopreservation solution is added before freezing. Various cryopreservation solutions are available commercially, most of which contain varying proportions of glycerol and albumin. After freezing, the samples are immersed in liquid nitrogen.

Several techniques have been developed to try to reduce damage caused by freezing and thawing, including:

- One-step freezing method [258, 259]: sample is held in the vapour phase for 10 min before being plunged into liquid nitrogen.
- Slow or multi-step method [260]: sample is gradually cooled in the vapour phase for approximately 40 min. A programmable automatic freezing machine, which is preset to cool at a rate of 1-10°C/min is used.

The method available depends on the resources of the laboratory. Whichever freezing technique is used, it should be tested using donor sperm and post-thaw examination, and should regularly undergo a quality-control programme. The likelihood of sperm survival decreases with repeated freezing and thawing. The maximum viable storage time for human sperm is not known.

3M.2.2 *Cryopreservation of small numbers of sperm*

Standard cryopreservation in straws is an efficient way of storing large numbers of sperm (e.g., for a donor insemination programme). However, in micro-TESE, few sperm might be obtained, and the choice is either to freeze testicular tissue and find sperm after thawing the tissue, or to freeze small numbers of sperm. If sperm are frozen in straws, it can be difficult to find any sperm after thawing. Instead, the sperm should be frozen in a pellet [261] or in a container [262].

3M.2.3 *Testing for infections and preventing cross-contamination*

Sperm storage in straws is used extensively. Large numbers of straws are stored in canisters, with the straws being bathed in a pool of liquid nitrogen. Microbial contamination of the pool of liquid nitrogen results in

contamination of the outside of all the straws [263]. The most widely used safeguard is to use so-called high security closed straws. According to the European directives 2004/23 and 2006/17, samples should be tested for hepatitis B and C and human immunodeficiency virus (HIV). In case of non-partner donation, samples are also tested for C. Trachomatis (by Nucleic Acid Testing [NAT]) and syphilis, as well as genetics, that is, karyotype and most prevalent genetic disorders in the population to which the non-partner donor belongs. Until the test results are known, samples must be stored in an individual quarantine vessel (separate storage). If open straws are used (e.g., for vitrification purposes) some laboratories use the additional safeguard of double-wrapping the straws before freezing, although this is more costly. Some centres carry out cytomegalovirus testing and store negative and positive samples separately. Considerable ethical issues surround the storage of samples before cancer chemotherapy in men who are hepatitis-virus- or HIV-positive. Few clinics have separate storage facilities for HIV-positive samples. However, the success of antiretroviral treatment is increasing the number of HIV-positive men who may wish to store sperm. There is also concern about HIV transmission to children conceived using HIV-positive sperm, because sperm-washing techniques fail in ~5% of cases.

3M.2.4 **Fail-safe precautions to prevent loss of stored materials**

Any laboratory that undertakes long-term storage of human biological materials should have procedures that guard against accidental loss of material caused by storage vessel failure. This is particularly important for sperm stored before potentially sterilising cancer chemotherapy, because these patients may not be able to obtain further sperm.

3M.2.5 **Orphan samples**

In malignancy and some other situations, several years might pass before stored samples are required. Inevitably, during this time, the owners of some samples might disappear or die, leaving behind orphan samples for which the owner is no longer contactable. The duty of the laboratory and the legal ownership of these samples can create considerable problems.

3M.3 **Biological aspects**

Cryopreservation induces deterioration of semen quality. After the sample has been thawed, motility [264] and morphology [265, 266] are worsened, including mitochondrial acrosomal and sperm tail damage [255]. Sperm freezing decreases motility by 31% and mitochondrial activity by 36%, and causes morphological disruption in 37% of sperm [258]. Motility is correlated best with IVF capacity of the thawed sample. Further improvement can be achieved by selecting the subpopulation of sperm with the best motility and DNA integrity and freezing these sperm in seminal plasma [261].

3M.4 **Conclusions and recommendations for semen cryopreservation**

Conclusions	LE
The purpose of sperm cryopreservation is to enable future assisted reproduction techniques procedures.	1b
Cryopreservation techniques are not optimal, and future efforts are needed to improve the outcome of sperm banking.	3

Recommendations	GR
Cryopreservation of semen should be offered to all men who are candidates for chemotherapy, radiation or surgical interventions that might interfere with spermatogenesis or cause ejaculatory disorders.	A
If testicular biopsies are indicated, sperm cryopreservation is strongly advised.	A
If cryopreservation is not available locally, patients should be advised about the possibility of visiting, or transferring to, the nearest cryopreservation unit before therapy starts.	C
Consent for cryopreservation should include a record of the man's wishes for his samples if he dies or is otherwise untraceable.	C
Precautions should be taken to prevent transmission of viral, sexually transmitted or any other infection by cryostored materials from donor to recipient, and to prevent contamination of stored samples. These precautions include testing of the patient and the use of rapid testing and quarantine of samples until test results are known. Samples from men who are positive for hepatitis virus or HIV should not be stored in the same container as samples from men who have been tested and are free from infection.	C

4. REFERENCES

1. Dohle GR, et al. EAU guidelines on male infertility. *Eur Urol* 2005 48(5): p. 703-11. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/16005562>
2. Dohle GR, et al. European Association of Urology guidelines on vasectomy. *Eur Urol* 2012 61(1): p. 159-63.
<http://www.ncbi.nlm.nih.gov/pubmed/22033172>
3. Jungwirth A, et al. European Association of Urology guidelines on Male Infertility: the 2012 update. *Eur Urol* 2012 62(2): p. 324-32.
<http://www.ncbi.nlm.nih.gov/pubmed/22591628>
4. World Health Organization. WHO Manual for the Standardized Investigation and Diagnosis of the Infertile Couple. 2000, Cambridge University Press: Cambridge.
5. Greenhall E, et al. The prevalence of subfertility: a review of the current confusion and a report of two new studies. *Fertil Steril* 1990 54(6): p. 978-83.
<http://www.ncbi.nlm.nih.gov/pubmed/2245856>
6. Andrology, In: Nieschlag E, Behre HM and Nieschlag S (eds). Male reproductive health and dysfunction, in *Male reproductive health and dysfunction*. 2010, Springer Verlag: Berlin.
7. Snick HK, et al. The spontaneous pregnancy prognosis in untreated subfertile couples: the Walcheren primary care study. *Hum Reprod* 1997 12(7): p. 1582-8.
<http://www.ncbi.nlm.nih.gov/pubmed/9262301>
8. Rowe T. Fertility and a woman's age. *J Reprod Med* 2006 51(3): p. 157-63.
<http://www.ncbi.nlm.nih.gov/pubmed/16674009>
9. World Health Organization. WHO Laboratory Manual for the Examination and Processing of Human Semen, in 5th edn. 2010.
10. World Health Organization. WHO Manual for the Standardized Investigation, Diagnosis and Management of the Infertile Male. 2000, Cambridge University Press: Cambridge.
11. Hauser R, et al. Fertility in cases of hypergonadotropic azoospermia. *Fertil Steril* 1995 63(3): p. 631-6.
<http://www.ncbi.nlm.nih.gov/pubmed/7851598>
12. Martin-du-Pan RC, et al. Increased follicle stimulating hormone in infertile men. Is increased plasma FSH always due to damaged germinal epithelium? *Hum Reprod* 1995 10(8): p. 1940-5. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/8567817>
13. Abdel-Meguid TA. Predictors of sperm recovery and azoospermia relapse in men with nonobstructive azoospermia after varicocele repair. *J Urol* 2012 187(1): p. 222-6.
<http://www.ncbi.nlm.nih.gov/pubmed/22100001>
14. Colpi GM, et al. Sperm retrieval for intra-cytoplasmic sperm injection in non-obstructive azoospermia. *Minerva Urol Nefrol* 2005 57(2): p. 99-107.
<http://www.ncbi.nlm.nih.gov/pubmed/15951734>
15. Kim ED, et al. Testis biopsies frequently demonstrate sperm in men with azoospermia and significantly elevated follicle-stimulating hormone levels. *J Urol* 1997 157(1): p. 144-6.
<http://www.ncbi.nlm.nih.gov/pubmed/8976237>
16. Deruyver Y, et al. Outcome of microdissection TESE compared with conventional TESE in non-obstructive azoospermia: a systematic review. *Andrology* 2014 2(1): p. 20-4.
<http://www.ncbi.nlm.nih.gov/pubmed/24193894>
17. Marconi M, et al. Combined trifocal and microsurgical testicular sperm extraction is the best technique for testicular sperm retrieval in "low-chance" nonobstructive azoospermia. *Eur Urol* 2012 62(4): p. 713-9.
<http://www.ncbi.nlm.nih.gov/pubmed/22521095>
18. Schlegel PN. Testicular sperm extraction: microdissection improves sperm yield with minimal tissue excision. *Hum Reprod* 1999 14(1): p. 131-5.
<http://www.ncbi.nlm.nih.gov/pubmed/10374109>
19. Schwarzer JU, et al. No relationship between biopsy sites near the main testicular vessels or rete testis and successful sperm retrieval using conventional or microdissection biopsies in 220 non-obstructive azoospermic men. *Asian J Androl* 2013 15(6): p. 795-8.
<http://www.ncbi.nlm.nih.gov/pubmed/24013619>
20. Ben-Yosef D, et al. Testicular sperm retrieval and cryopreservation prior to initiating ovarian stimulation as the first line approach in patients with non-obstructive azoospermia. *Hum Reprod* 1999 14(7): p. 1794-801.
<http://www.ncbi.nlm.nih.gov/pubmed/10402392>

21. Borges E, Jr., et al. Testicular sperm results in elevated miscarriage rates compared to epididymal sperm in azoospermic patients. *Sao Paulo Med J* 2002 120(4): p. 122-6.
<http://www.ncbi.nlm.nih.gov/pubmed/12436160>
22. Ghanem M, et al. Comparison of the outcome of intracytoplasmic sperm injection in obstructive and non-obstructive azoospermia in the first cycle: a report of case series and meta-analysis. *Int J Androl* 2005 28(1): p. 16-21.
<http://www.ncbi.nlm.nih.gov/pubmed/15679616>
23. Gil Salom M. [Spermatid recovery techniques for intracytoplasmic spermatozoid injection (ICSI) in male infertility]. *Arch Esp Urol* 2004 57(9): p. 1035-46.
<http://www.ncbi.nlm.nih.gov/pubmed/15624403>
24. Schwarzer JU, et al. Sperm retrieval procedures and intracytoplasmic spermatozoa injection with epididymal and testicular sperms. *Urol Int* 2003 70(2): p. 119-23.
<http://www.ncbi.nlm.nih.gov/pubmed/12592040>
25. Vernaeva V, et al. Intracytoplasmic sperm injection with testicular spermatozoa is less successful in men with nonobstructive azoospermia than in men with obstructive azoospermia. *Fertil Steril* 2003 79(3): p. 529-33.
<http://www.ncbi.nlm.nih.gov/pubmed/12620435>
26. Belva F, et al. Neonatal outcome of 724 children born after ICSI using non-ejaculated sperm. *Hum Reprod* 2011 26(7): p. 1752-8.
<http://www.ncbi.nlm.nih.gov/pubmed/21511713>
27. Hauser R, et al. Severe hypospermatogenesis in cases of nonobstructive azoospermia: should we use fresh or frozen testicular spermatozoa? *J Androl* 2005 26(6): p. 772-8.
<http://www.ncbi.nlm.nih.gov/pubmed/16291973>
28. Carrell DT. The clinical implementation of sperm chromosome aneuploidy testing: pitfalls and promises. *J Androl* 2008 29(2): p. 124-33.
<http://www.ncbi.nlm.nih.gov/pubmed/17881765>
29. Johnson MD. Genetic risks of intracytoplasmic sperm injection in the treatment of male infertility: recommendations for genetic counseling and screening. *Fertil Steril* 1998 70(3): p. 397-411.
<http://www.ncbi.nlm.nih.gov/pubmed/9757865>
30. Clementini E, et al. Prevalence of chromosomal abnormalities in 2078 infertile couples referred for assisted reproductive techniques. *Hum Reprod* 2005 20(2): p. 437-42.
<http://www.ncbi.nlm.nih.gov/pubmed/15567875>
31. Vincent MC, et al. Cytogenetic investigations of infertile men with low sperm counts: a 25-year experience. *J Androl* 2002 23(1): p. 18-22; discussion 44-5. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/11780918>
32. Dul EC, et al. The prevalence of chromosomal abnormalities in subgroups of infertile men. *Hum Reprod* 2012 27(1): p. 36-43.
<http://www.ncbi.nlm.nih.gov/pubmed/22081244>
33. Davila Garza SA, et al. Reproductive outcomes in patients with male infertility because of Klinefelter's syndrome, Kartagener's syndrome, round-head sperm, dysplasia fibrous sheath, and 'stump' tail sperm: an updated literature review. *Curr Opin Obstet Gynecol* 2013 25(3): p. 229-46.
<http://www.ncbi.nlm.nih.gov/pubmed/23587797>
34. Wang C, et al. Hormonal studies in Klinefelter's syndrome. *Clin Endocrinol (Oxf)* 1975 4(4): p. 399-411.
<http://www.ncbi.nlm.nih.gov/pubmed/1157343>
35. Staessen C, et al. PGD in 47,XXY Klinefelter's syndrome patients. *Hum Reprod Update* 2003 9(4): p. 319-30.
<http://www.ncbi.nlm.nih.gov/pubmed/12926526>
36. Chevret E, et al. Increased incidence of hyperhaploid 24,XY spermatozoa detected by three-colour FISH in a 46,XY/47,XXY male. *Hum Genet* 1996 97(2): p. 171-5.
<http://www.ncbi.nlm.nih.gov/pubmed/8566948>
37. Martini E, et al. Constitution of semen samples from XYY and XXY males as analysed by in-situ hybridization. *Hum Reprod* 1996 11(8): p. 1638-43.
<http://www.ncbi.nlm.nih.gov/pubmed/8921108>
38. Cozzi J, et al. Achievement of meiosis in XXY germ cells: study of 543 sperm karyotypes from an XY/XXY mosaic patient. *Hum Genet* 1994 93(1): p. 32-4.
<http://www.ncbi.nlm.nih.gov/pubmed/8270252>
39. Estop AM, et al. Meiotic products of a Klinefelter 47,XXY male as determined by sperm fluorescence in-situ hybridization analysis. *Hum Reprod* 1998 13(1): p. 124-7.
<http://www.ncbi.nlm.nih.gov/pubmed/9512242>

40. Foresta C, et al. High incidence of sperm sex chromosomes aneuploidies in two patients with Klinefelter's syndrome. *J Clin Endocrinol Metab* 1998 83(1): p. 203-5.
<http://www.ncbi.nlm.nih.gov/pubmed/9435442>
41. Guttenbach M, et al. Segregation of sex chromosomes into sperm nuclei in a man with 47,XXY Klinefelter's karyotype: a FISH analysis. *Hum Genet* 1997 99(4): p. 474-7.
<http://www.ncbi.nlm.nih.gov/pubmed/9099836>
42. Gianaroli L, et al. Frequency of aneuploidy in sperm from patients with extremely severe male factor infertility. *Hum Reprod* 2005 20(8): p. 2140-52.
<http://www.ncbi.nlm.nih.gov/pubmed/15845594>
43. Pang MG, et al. The high incidence of meiotic errors increases with decreased sperm count in severe male factor infertilities. *Hum Reprod* 2005 20(6): p. 1688-94.
<http://www.ncbi.nlm.nih.gov/pubmed/15734753>
44. Tempest HG, et al. Cytogenetic risks in chromosomally normal infertile men. *Curr Opin Obstet Gynecol* 2009 21(3): p. 223-7.
<http://www.ncbi.nlm.nih.gov/pubmed/19424064>
45. Baccetti B, et al. Ultrastructural studies of spermatozoa from infertile males with Robertsonian translocations and 18, X, Y aneuploidies. *Hum Reprod* 2005 20(8): p. 2295-300.
<http://www.ncbi.nlm.nih.gov/pubmed/15878922>
46. Miyagawa Y, et al. Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: a 30-year retrospective study. *J Urol* 2005 173(6): p. 2072-5.
<http://www.ncbi.nlm.nih.gov/pubmed/15879837>
47. Ferlin A, et al. Male infertility and androgen receptor gene mutations: clinical features and identification of seven novel mutations. *Clin Endocrinol (Oxf)* 2006 65(5): p. 606-10.
<http://www.ncbi.nlm.nih.gov/pubmed/17054461>
48. Gottlieb B, et al. Molecular pathology of the androgen receptor in male (in)fertility. *Reprod Biomed Online* 2005 10(1): p. 42-8.
<http://www.ncbi.nlm.nih.gov/pubmed/15705293>
49. Rajender S, et al. Phenotypic heterogeneity of mutations in androgen receptor gene. *Asian J Androl* 2007 9(2): p. 147-79.
<http://www.ncbi.nlm.nih.gov/pubmed/17334586>
50. Tincello DG, et al. Preliminary investigations on androgen receptor gene mutations in infertile men. *Mol Hum Reprod* 1997 3(11): p. 941-3.
<http://www.ncbi.nlm.nih.gov/pubmed/9433918>
51. Giwercman A, et al. Preserved male fertility despite decreased androgen sensitivity caused by a mutation in the ligand-binding domain of the androgen receptor gene. *J Clin Endocrinol Metab* 2000 85(6): p. 2253-9.
<http://www.ncbi.nlm.nih.gov/pubmed/10852459>
52. Wang PJ. X chromosomes, retrogenes and their role in male reproduction. *Trends Endocrinol Metab* 2004 15(2): p. 79-83.
<http://www.ncbi.nlm.nih.gov/pubmed/15036254>
53. Nuti F, et al. Gene polymorphisms/mutations relevant to abnormal spermatogenesis. *Reprod Biomed Online* 2008 16(4): p. 504-13.
<http://www.ncbi.nlm.nih.gov/pubmed/18413059>
54. Stouffs K, et al. Male infertility and the involvement of the X chromosome. *Hum Reprod Update* 2009 15(6): p. 623-37.
<http://www.ncbi.nlm.nih.gov/pubmed/19515807>
55. Krausz C, et al. High resolution X chromosome-specific array-CGH detects new CNVs in infertile males. *PLoS One* 2012 7(10): p. e44887.
<http://www.ncbi.nlm.nih.gov/pubmed/23056185>
56. Tuttelmann F, et al. Copy number variants in patients with severe oligozoospermia and Sertoli-cell-only syndrome. *PLoS One* 2011 6(4): p. e19426.
<http://www.ncbi.nlm.nih.gov/pubmed/21559371>
57. Vogt PH, et al. Human Y chromosome azoospermia factors (AZF) mapped to different subregions in Yq11. *Hum Mol Genet* 1996 5(7): p. 933-43.
<http://www.ncbi.nlm.nih.gov/pubmed/8817327>
58. Krausz C, et al. Y chromosome and male infertility: update, 2006. *Front Biosci* 2006 11: p. 3049-61.
<http://www.ncbi.nlm.nih.gov/pubmed/16720375>

59. Skaletsky H, et al. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. *Nature* 2003 423(6942): p. 825-37.
<http://www.ncbi.nlm.nih.gov/pubmed/12815422>
60. Tyler-Smith C, et al. The will-o'-the-wisp of genetics--hunting for the azoospermia factor gene. *N Engl J Med* 2009 360(9): p. 925-7. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/19246366>
61. Krausz C, et al. The Y chromosome and male fertility and infertility. *Int J Androl* 2003 26(2): p. 70-5.
<http://www.ncbi.nlm.nih.gov/pubmed/12641824>
62. Krausz C, et al. EAA/EMQN best practice guidelines for molecular diagnosis of Y-chromosomal microdeletions: state-of-the-art 2013. *Andrology* 2014 2(1): p. 5-19.
<http://www.ncbi.nlm.nih.gov/pubmed/24357628>
63. Stuppia L, et al. A quarter of men with idiopathic oligo-azoospermia display chromosomal abnormalities and microdeletions of different types in interval 6 of Yq11. *Hum Genet* 1998 102(5): p. 566-70.
<http://www.ncbi.nlm.nih.gov/pubmed/9654206>
64. Le Bourhis C, et al. Y chromosome microdeletions and germinal mosaicism in infertile males. *Mol Hum Reprod* 2000 6(8): p. 688-93.
<http://www.ncbi.nlm.nih.gov/pubmed/10908277>
65. Siffroi JP, et al. Sex chromosome mosaicism in males carrying Y chromosome long arm deletions. *Hum Reprod* 2000 15(12): p. 2559-62.
<http://www.ncbi.nlm.nih.gov/pubmed/11098026>
66. Patsalis PC, et al. Effects of transmission of Y chromosome AZFc deletions. *Lancet* 2002 360(9341): p. 1222-4.
<http://www.ncbi.nlm.nih.gov/pubmed/12401251>
67. Simoni M, et al. EAA/EMQN best practice guidelines for molecular diagnosis of y-chromosomal microdeletions. State of the art 2004. *Int J Androl* 2004 27(4): p. 240-9.
<http://www.ncbi.nlm.nih.gov/pubmed/15271204>
68. Repping S, et al. Polymorphism for a 1.6-Mb deletion of the human Y chromosome persists through balance between recurrent mutation and haploid selection. *Nat Genet* 2003 35(3): p. 247-51.
<http://www.ncbi.nlm.nih.gov/pubmed/14528305>
69. Giachini C, et al. Partial AZFc deletions and duplications: clinical correlates in the Italian population. *Hum Genet* 2008 124(4): p. 399-410.
<http://www.ncbi.nlm.nih.gov/pubmed/18807255>
70. Navarro-Costa P, et al. The AZFc region of the Y chromosome: at the crossroads between genetic diversity and male infertility. *Hum Reprod Update* 2010 16(5): p. 525-42.
<http://www.ncbi.nlm.nih.gov/pubmed/20304777>
71. Stouffs K, et al. What about gr/gr deletions and male infertility? Systematic review and meta-analysis. *Hum Reprod Update* 2011 17(2): p. 197-209.
<http://www.ncbi.nlm.nih.gov/pubmed/20959348>
72. Nathanson KL, et al. The Y deletion gr/gr and susceptibility to testicular germ cell tumor. *Am J Hum Genet* 2005 77(6): p. 1034-43.
<http://www.ncbi.nlm.nih.gov/pubmed/16380914>
73. Zhang F, et al. Partial deletions are associated with an increased risk of complete deletion in AZFc: a new insight into the role of partial AZFc deletions in male infertility. *J Med Genet* 2007 44(7): p. 437-44.
<http://www.ncbi.nlm.nih.gov/pubmed/17412880>
74. Donat R, et al. The incidence of cystic fibrosis gene mutations in patients with congenital bilateral absence of the vas deferens in Scotland. *Br J Urol* 1997 79(1): p. 74-7.
<http://www.ncbi.nlm.nih.gov/pubmed/9043501>
75. Chillon M, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. *N Engl J Med* 1995 332(22): p. 1475-80.
<http://www.ncbi.nlm.nih.gov/pubmed/7739684>
76. De Braekeleer M, et al. Mutations in the cystic fibrosis gene in men with congenital bilateral absence of the vas deferens. *Mol Hum Reprod* 1996 2(9): p. 669-77.
<http://www.ncbi.nlm.nih.gov/pubmed/9239681>
77. Augarten A, et al. Congenital bilateral absence of vas deferens in the absence of cystic fibrosis. *Lancet* 1994 344(8935): p. 1473-4.
78. Drake MJ, et al. Absent vas deferens and ipsilateral multicystic dysplastic kidney in a child. *Br J Urol* 1996 77(5): p. 756-7. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/8689131>

79. Krausz C, et al. Genetic risk factors in male infertility. *Arch Androl* 2007 53(3): p. 125-33.
<http://www.ncbi.nlm.nih.gov/pubmed/17612870>
80. Tuttelmann F, et al. Gene polymorphisms and male infertility--a meta-analysis and literature review. *Reprod Biomed Online* 2007 15(6): p. 643-58.
<http://www.ncbi.nlm.nih.gov/pubmed/18062861>
81. ESHRE Capri Workshop Group. Intracytoplasmic sperm injection (ICSI) in 2006: evidence and evolution. *Hum Reprod Update* 2007 13(6): p. 515-26.
<http://www.ncbi.nlm.nih.gov/pubmed/17630396>
82. Davies MJ, et al. Reproductive technologies and the risk of birth defects. *N Engl J Med* 2012 366(19): p. 1803-13.
<http://www.ncbi.nlm.nih.gov/pubmed/22559061>
83. Van Steirteghem A, et al. Follow-up of children born after ICSI. *Hum Reprod Update* 2002 8(2): p. 111-6.
<http://www.ncbi.nlm.nih.gov/pubmed/12099626>
84. Zini A, et al. Are tests of sperm DNA damage clinically useful? Pros and cons. *J Androl* 2009 30(3): p. 219-29.
<http://www.ncbi.nlm.nih.gov/pubmed/19059901>
85. Hendry W, Azoospermia and surgery for testicular obstruction. In: Hargreave TB (ed). *Male Infertility*. 1997, Springer Verlag: Berlin.
86. Hendry WF, et al. Exploratory scrototomy in 168 azoospermic males. *Br J Urol* 1983 55(6): p. 785-91.
<http://www.ncbi.nlm.nih.gov/pubmed/6652453>
87. Jequier AM. Obstructive azoospermia: a study of 102 patients. *Clin Reprod Fertil* 1985 3(1): p. 21-36.
<http://www.ncbi.nlm.nih.gov/pubmed/3978535>
88. Pierik FH, et al. Serum inhibin B as a marker of spermatogenesis. *J Clin Endocrinol Metab* 1998 83(9): p. 3110-4.
<http://www.ncbi.nlm.nih.gov/pubmed/9745412>
89. Oates RD, et al. The genetic basis of congenital bilateral absence of the vas deferens and cystic fibrosis. *J Androl* 1994 15(1): p. 1-8. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/8188533>
90. Handelsman DJ, et al. Young's syndrome. Obstructive azoospermia and chronic sinopulmonary infections. *N Engl J Med* 1984 310(1): p. 3-9.
<http://www.ncbi.nlm.nih.gov/pubmed/6689737>
91. Schoysman R. Vaso-epididymostomy--a survey of techniques and results with considerations of delay of appearance of spermatozoa after surgery. *Acta Eur Fertil* 1990 21(5): p. 239-45.
<http://www.ncbi.nlm.nih.gov/pubmed/2132475>
92. Silber SJ, et al. Microscopic vasectomy reversal 30 years later: a summary of 4010 cases by the same surgeon. *J Androl* 2004 25(6): p. 845-59. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/15477352>
93. Jarvi K, et al. Adverse effects on vasoepididymostomy outcomes for men with concomitant abnormalities in the prostate and seminal vesicle. *J Urol* 1998 160(4): p. 1410-2.
<http://www.ncbi.nlm.nih.gov/pubmed/9751365>
94. Matthews GJ, et al. Patency following microsurgical vasoepididymostomy and vasovasostomy: temporal considerations. *J Urol* 1995 154(6): p. 2070-3.
<http://www.ncbi.nlm.nih.gov/pubmed/7500460>
95. McVicar CM, et al. Effects of vasectomy on spermatogenesis and fertility outcome after testicular sperm extraction combined with ICSI. *Hum Reprod* 2005 20(10): p. 2795-800.
<http://www.ncbi.nlm.nih.gov/pubmed/15958397>
96. Borovikov A. Treatment of large vasal defects. In: Goldstein M (ed). *Surgery of Male Infertility*. 1995 WB Saunders: Philadelphia. p. 77-95.
97. Shin D, et al. Herniorrhaphy with polypropylene mesh causing inguinal vasal obstruction: a preventable cause of obstructive azoospermia. *Ann Surg* 2005 241(4): p. 553-8.
<http://www.ncbi.nlm.nih.gov/pubmed/15798455>
98. Schlegel PN, et al. Urogenital anomalies in men with congenital absence of the vas deferens. *J Urol* 1996 155(5): p. 1644-8.
<http://www.ncbi.nlm.nih.gov/pubmed/8627844>
99. Elder JS, et al. Cyst of the ejaculatory duct/urogenital sinus. *J Urol* 1984 132(4): p. 768-71.
<http://www.ncbi.nlm.nih.gov/pubmed/6471229>

100. Schuhrke TD, et al. Prostatic utricle cysts (mullerian duct cysts). *J Urol* 1978 119(6): p. 765-7.
<http://www.ncbi.nlm.nih.gov/pubmed/26814>
101. Surya BV, et al. Cysts of the seminal vesicles: diagnosis and management. *Br J Urol* 1988 62(5): p. 491-3. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/3208033>
102. Schroeder-Printzen I, et al. Surgical therapy in infertile men with ejaculatory duct obstruction: technique and outcome of a standardized surgical approach. *Hum Reprod* 2000 15(6): p. 1364-8.
<http://www.ncbi.nlm.nih.gov/pubmed/10831570>
103. Kuligowska E, et al. Male infertility: role of transrectal US in diagnosis and management. *Radiology* 1992 185(2): p. 353-60.
<http://www.ncbi.nlm.nih.gov/pubmed/1410338>
104. Colpi GM, et al. Functional voiding disturbances of the ampullo-vesicular seminal tract: a cause of male infertility. *Acta Eur Fertil* 1987 18(3): p. 165-79.
<http://www.ncbi.nlm.nih.gov/pubmed/3125711>
105. Silber SJ, et al. Pregnancy with sperm aspiration from the proximal head of the epididymis: a new treatment for congenital absence of the vas deferens. *Fertil Steril* 1988 50(3): p. 525-8. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/3410105>
106. Esteves SC, et al. Sperm retrieval techniques for assisted reproduction. *Int Braz J Urol* 2011 37(5): p. 570-83.
<http://www.ncbi.nlm.nih.gov/pubmed/22099268>
107. Schroeder-Printzen I, et al. Microsurgical epididymal sperm aspiration: aspirate analysis and straws available after cryopreservation in patients with non-reconstructable obstructive azoospermia. MESA/TESE Group Giessen. *Hum Reprod* 2000 15(12): p. 2531-5.
<http://www.ncbi.nlm.nih.gov/pubmed/11098022>
108. Van Peperstraten A, et al. Techniques for surgical retrieval of sperm prior to ICSI for azoospermia. *Cochrane Database Syst Rev* 2006(3): p. CD002807.
<http://www.ncbi.nlm.nih.gov/pubmed/16855991>
109. Chan PT, et al. Prospective analysis of outcomes after microsurgical intussusception vasoepididymostomy. *BJU Int* 2005 96(4): p. 598-601.
<http://www.ncbi.nlm.nih.gov/pubmed/16104917>
110. Mangoli V, et al. The outcome of ART in males with impaired spermatogenesis. *J Hum Reprod Sci* 2008 1(2): p. 73-6.
<http://www.ncbi.nlm.nih.gov/pubmed/19562049>
111. Kolettis PN, et al. Vasoepididymostomy for vasectomy reversal: a critical assessment in the era of intracytoplasmic sperm injection. *J Urol* 1997 158(2): p. 467-70.
<http://www.ncbi.nlm.nih.gov/pubmed/9224325>
112. Ruiz-Romero J, et al. A new device for microsurgical sperm aspiration. *Andrologia* 1994 26(2): p. 119-20. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/8042769>
113. Fisch H, et al. Management of ejaculatory duct obstruction: etiology, diagnosis, and treatment. *World J Urol* 2006 24(6): p. 604-10.
<http://www.ncbi.nlm.nih.gov/pubmed/17077974>
114. World Health Organization. WHO Manual for the Standardized Investigation, Diagnosis and Management of the Infertile Male. 2000, Cambridge University Press: Cambridge.
115. [No authors listed] The influence of varicocele on parameters of fertility in a large group of men presenting to infertility clinics. World Health Organization. *Fertil Steril* 1992 57(6): p. 1289-93.
<http://www.ncbi.nlm.nih.gov/pubmed/1601152>
116. Agarwal A, et al. Efficacy of varicocelectomy in improving semen parameters: new meta-analytical approach. *Urology* 2007 70(3): p. 532-8.
<http://www.ncbi.nlm.nih.gov/pubmed/17905111>
117. Zini A, et al. Are varicoceles associated with increased deoxyribonucleic acid fragmentation? *Fertil Steril* 2011 96(6): p. 1283-7.
<http://www.ncbi.nlm.nih.gov/pubmed/22035729>
118. Evers JH, et al. Surgery or embolisation for varicoceles in subfertile men. *Cochrane Database Syst Rev* 2009(1): p. CD000479.
<http://www.ncbi.nlm.nih.gov/pubmed/19160180>
119. Baazeem A, et al. Varicocele and male factor infertility treatment: a new meta-analysis and review of the role of varicocele repair. *Eur Urol* 2011 60(4): p. 796-808.
<http://www.ncbi.nlm.nih.gov/pubmed/21733620>

120. Ding H, et al. Open non-microsurgical, laparoscopic or open microsurgical varicocelectomy for male infertility: a meta-analysis of randomized controlled trials. *BJU Int* 2012 110(10): p. 1536-42.
<http://www.ncbi.nlm.nih.gov/pubmed/22642226>
121. Tauber R, et al. Antegrade scrotal sclerotherapy for the treatment of varicocele: technique and late results. *J Urol* 1994 151(2): p. 386-90.
<http://www.ncbi.nlm.nih.gov/pubmed/8283530>
122. Sigmund G, et al. Idiopathic varicoceles: feasibility of percutaneous sclerotherapy. *Radiology* 1987 164(1): p. 161-8.
<http://www.ncbi.nlm.nih.gov/pubmed/3588899>
123. Lenk S, et al. Comparison of different methods of treating varicocele. *J Androl* 1994 15 Suppl: p. 34S-37S.
<http://www.ncbi.nlm.nih.gov/pubmed/7721674>
124. Seyferth W, et al. Percutaneous sclerotherapy of varicocele. *Radiology* 1981 139(2): p. 335-40.
<http://www.ncbi.nlm.nih.gov/pubmed/7220877>
125. Ivanissevich O. Left varicocele due to reflux; experience with 4,470 operative cases in forty-two years. *J Int Coll Surg* 1960 34: p. 742-55. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/13718224>
126. Palomo A. Radical cure of varicocele by a new technique; preliminary report. *J Urol* 1949 61(3): p. 604-7. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/18114752>
127. Goldstein M, et al. Microsurgical inguinal varicocelectomy with delivery of the testis: an artery and lymphatic sparing technique. *J Urol* 1992 148(6): p. 1808-11.
<http://www.ncbi.nlm.nih.gov/pubmed/1433614>
128. Jungwirth A, et al. Clinical outcome of microsurgical subinguinal varicocelectomy in infertile men. *Andrologia* 2001 33(2): p. 71-4.
<http://www.ncbi.nlm.nih.gov/pubmed/11350369>
129. Miersch WD, et al. Laparoscopic varicocelectomy: indication, technique and surgical results. *Br J Urol* 1995 76(5): p. 636-8.
<http://www.ncbi.nlm.nih.gov/pubmed/8535687>
130. Tan SM, et al. Laparoscopic varicocelectomy: technique and results. *Br J Urol* 1995 75(4): p. 523-8.
<http://www.ncbi.nlm.nih.gov/pubmed/7788264>
131. Bianco SD, et al. The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism. *Nat Rev Endocrinol* 2009 5(10): p. 569-76.
<http://www.ncbi.nlm.nih.gov/pubmed/19707180>
132. Krausz C. Genetic aspects of male infertility. *European Urological Review* 2009 3(2).
<http://www.ncbi.nlm.nih.gov/pubmed/17612870>
133. Schopohl J, et al. Comparison of gonadotropin-releasing hormone and gonadotropin therapy in male patients with idiopathic hypothalamic hypogonadism. *Fertil Steril* 1991 56(6): p. 1143-50.
<http://www.ncbi.nlm.nih.gov/pubmed/1743335>
134. Andersson AM, et al. Impaired Leydig cell function in infertile men: a study of 357 idiopathic infertile men and 318 proven fertile controls. *J Clin Endocrinol Metab* 2004 89(7): p. 3161-7.
<http://www.ncbi.nlm.nih.gov/pubmed/15240588>
135. Lanfranco F, et al. Klinefelter's syndrome. *Lancet* 2004 364(9430): p. 273-83.
<http://www.ncbi.nlm.nih.gov/pubmed/15262106>
136. Manning M, et al. Decrease in testosterone blood concentrations after testicular sperm extraction for intracytoplasmic sperm injection in azoospermic men. *Lancet* 1998 352(9121): p. 37. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/9800753>
137. Finkelstein J. Androgens and bone metabolism. In: Nieschlag E, Behre HM (eds). *Testosterone: Action, Deficiency, Substitution*. 2nd edition., in *Testosterone: Action, Deficiency, Substitution*. 1998, Springer Verlag: Berlin. p. 187-207.
138. Dohle G, et al. Guidelines on Male Hypogonadism. In: *EAU Guidelines*, edn. presented on the 27th EAU Annual Congress, Paris 2012.
<http://www.uroweb.org/guidelines/online-guidelines/>
139. Nieschlag E, et al. *Guidelines for the Use of Androgens in Men*. 1992, WHO: Geneva.
<http://apps.who.int/iris/handle/10665/60776>
140. Skakkebaek NE, et al. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. *Hum Reprod* 2001 16(5): p. 972-8.
<http://www.ncbi.nlm.nih.gov/pubmed/11331648>

141. Heyns CF, et al. Historical review of theories on testicular descent. *J Urol* 1995 153(3 Pt 1): p. 754-67. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/7861531>
142. Gracia J, et al. Clinical and anatomopathological study of 2000 cryptorchid testes. *Br J Urol* 1995 75(6): p. 697-701.
<http://www.ncbi.nlm.nih.gov/pubmed/7613821>
143. Ritzen EM. Undescended testes: a consensus on management. *Eur J Endocrinol* 2008 159 Suppl 1: p. S87-90.
<http://www.ncbi.nlm.nih.gov/pubmed/18728121>
144. Yavetz H, et al. Cryptorchidism: incidence and sperm quality in infertile men. *Andrologia* 1992 24(5): p. 293-7.
<http://www.ncbi.nlm.nih.gov/pubmed/1356318>
145. Wilkerson ML, et al. Fertility potential: a comparison of intra-abdominal and intracanalicular testes by age groups in children. *Horm Res* 2001 55(1): p. 18-20.
<http://www.ncbi.nlm.nih.gov/pubmed/11423737>
146. Miller KD, et al. Fertility after unilateral cryptorchidism. Paternity, time to conception, pretreatment testicular location and size, hormone and sperm parameters. *Horm Res* 2001 55(5): p. 249-53.
<http://www.ncbi.nlm.nih.gov/pubmed/11740148>
147. Giwercman A, et al. Initiation of sperm production after bilateral orchiopexy: clinical and biological implications. *J Urol* 2000 163(4): p. 1255-6. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/10737515>
148. Giwercman A, et al. Prevalence of carcinoma in situ and other histopathological abnormalities in testes of men with a history of cryptorchidism. *J Urol* 1989 142(4): p. 998-1001: discussion 1001-2.
<http://www.ncbi.nlm.nih.gov/pubmed/2571738>
149. Pettersson A, et al. Age at surgery for undescended testis and risk of testicular cancer. *N Engl J Med* 2007 356(18): p. 1835-41.
<http://www.ncbi.nlm.nih.gov/pubmed/17476009>
150. Jones PF. Approaches to orchidopexy. *Br J Urol* 1995 75(6): p. 693-6. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/7613820>
151. Hadziselimovic F, et al. Infertility in cryptorchidism is linked to the stage of germ cell development at orchidopexy. *Horm Res* 2007 68(1): p. 46-52.
<http://www.ncbi.nlm.nih.gov/pubmed/17356291>
152. Kollin C, et al. Boys with undescended testes: endocrine, volumetric and morphometric studies on testicular function before and after orchidopexy at nine months or three years of age. *J Clin Endocrinol Metab* 2012 97(12): p. 4588-95.
<http://www.ncbi.nlm.nih.gov/pubmed/23015652>
153. Pierik FH, et al. The advantages of standardized evaluation of male infertility. *Int J Androl* 2000 23(6): p. 340-6.
<http://www.ncbi.nlm.nih.gov/pubmed/11114979>
154. Foresta C, et al. Suppression of the high endogenous levels of plasma FSH in infertile men are associated with improved Sertoli cell function as reflected by elevated levels of plasma inhibin B. *Hum Reprod* 2004 19(6): p. 1431-7.
<http://www.ncbi.nlm.nih.gov/pubmed/15117900>
155. Chua ME, et al. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. *Andrology* 2013 1(5): p. 749-57.
<http://www.ncbi.nlm.nih.gov/pubmed/23970453>
156. Showell MG, et al. Antioxidants for male subfertility. *Cochrane Database Syst Rev* 2011(1): p. CD007411.
<http://www.ncbi.nlm.nih.gov/pubmed/21249690>
157. Ross C, et al. A systematic review of the effect of oral antioxidants on male infertility. *Reprod Biomed Online* 2010 20(6): p. 711-23.
<http://www.ncbi.nlm.nih.gov/pubmed/20378409>
158. World Health Organization. Reproductive Health Strategy. Reproductive Health Research World Health Organisation, Geneva. Adopted at the 57th World Health Assembly. 2004
http://whqlibdoc.who.int/hq/2004/WHO_RHR_04.8.pdf
159. Handelsman DJ, et al. Traditional methods. In: Schill W, Comhaire F, Hargreave T (eds). *Andrology for the Clinician.*, in *Andrology for the Clinician*. 2006, Springer Verlag: Berlin. p. 122-124.
160. Matthiesson KL, et al. Male hormonal contraception: concept proven, product in sight? *Hum Reprod Update* 2006 12(4): p. 463-82.
<http://www.ncbi.nlm.nih.gov/pubmed/16597629>

161. Handelsman D, et al. Hormonal male contraception. In: Schill W, Comhaire F, Hargreave T (eds). *Andrology for the Clinician.*, in *Andrology for the Clinician*. 2006, Springer Verlag: Berlin.
162. Schwingl PJ, et al. Safety and effectiveness of vasectomy. *Fertil Steril* 2000 73(5): p. 923-36.
<http://www.ncbi.nlm.nih.gov/pubmed/10785217>
163. Holden CA, et al. Sexual activity, fertility and contraceptive use in middle-aged and older men: Men in Australia, Telephone Survey (MATEs). *Hum Reprod* 2005 20(12): p. 3429-34.
<http://www.ncbi.nlm.nih.gov/pubmed/16172145>
164. Li SQ, et al. The no-scalpel vasectomy. *J Urol* 1991 145(2): p. 341-4.
<http://www.ncbi.nlm.nih.gov/pubmed/1988727>
165. Nirapathpongporn A, et al. No-scalpel vasectomy at the King's birthday vasectomy festival. *Lancet* 1990 335(8694): p. 894-5.
<http://www.ncbi.nlm.nih.gov/pubmed/1969992>
166. Barone MA, et al. Effectiveness of vasectomy using cautery. *BMC Urol* 2004 4: p. 10.
<http://www.ncbi.nlm.nih.gov/pubmed/15260885>
167. Sokal D, et al. A comparison of vas occlusion techniques: cautery more effective than ligation and excision with fascial interposition. *BMC Urol* 2004 4(1): p. 12.
<http://www.ncbi.nlm.nih.gov/pubmed/15509302>
168. Sokal D, et al. Vasectomy by ligation and excision, with or without fascial interposition: a randomized controlled trial [ISRCTN77781689]. *BMC Med* 2004 2: p. 6.
<http://www.ncbi.nlm.nih.gov/pubmed/15056388>
169. Bernal-Delgado E, et al. The association between vasectomy and prostate cancer: a systematic review of the literature. *Fertil Steril* 1998 70(2): p. 191-200.
170. Christiansen CG, et al. Testicular pain following vasectomy: a review of postvasectomy pain syndrome. *J Androl* 2003 24(3): p. 293-8. [no abstract]
171. Verhulst AP, et al. Paternity after bilateral vasectomy. *BJU Int* 1999 83(3): p. 280-2.
<http://www.ncbi.nlm.nih.gov/pubmed/10233494>
172. Korthorst RA, et al. Clearance after vasectomy with a single semen sample containing < than 100 000 immotile sperm/mL: analysis of 1073 patients. *BJU Int* 2010 105(11): p. 1572-5.
<http://www.ncbi.nlm.nih.gov/pubmed/20002679>
173. Schroeder-Printzen I, et al. Vasovasostomy. *Urol Int* 2003 70(2): p. 101-7.
<http://www.ncbi.nlm.nih.gov/pubmed/12592037>
174. Belker AM, et al. Results of 1,469 microsurgical vasectomy reversals by the Vasovasostomy Study Group. *J Urol* 1991 145(3): p. 505-11.
<http://www.ncbi.nlm.nih.gov/pubmed/1997700>
175. Cook LA, et al. Vasectomy techniques for male sterilization: systematic Cochrane review of randomized controlled trials and controlled clinical trials. *Hum Reprod* 2004 19(11): p. 2431-8.
<http://www.ncbi.nlm.nih.gov/pubmed/15496598>
176. Heidenreich A, et al. Microsurgical vasovasostomy versus microsurgical epididymal sperm aspiration/testicular extraction of sperm combined with intracytoplasmic sperm injection. A cost-benefit analysis. *Eur Urol* 2000 37(5): p. 609-14.
<http://www.ncbi.nlm.nih.gov/pubmed/10765102>
177. Pavlovich CP, et al. Fertility options after vasectomy: a cost-effectiveness analysis. *Fertil Steril* 1997 67(1): p. 133-41.
<http://www.ncbi.nlm.nih.gov/pubmed/8986698>
178. Purvis K, et al. Infection in the male reproductive tract. Impact, diagnosis and treatment in relation to male infertility. *Int J Androl* 1993 16(1): p. 1-13.
<http://www.ncbi.nlm.nih.gov/pubmed/8468091>
179. Weidner W, et al. Relevance of male accessory gland infection for subsequent fertility with special focus on prostatitis. *Hum Reprod Update* 1999 5(5): p. 421-32.
<http://www.ncbi.nlm.nih.gov/pubmed/10582781>
180. Liversedge NH, et al. Antibiotic treatment based on seminal cultures from asymptomatic male partners in in-vitro fertilization is unnecessary and may be detrimental. *Hum Reprod* 1996 11(6): p. 1227-31.
<http://www.ncbi.nlm.nih.gov/pubmed/8671429>
181. Taylor-Robinson D. Evaluation and comparison of tests to diagnose *Chlamydia trachomatis* genital infections. *Hum Reprod* 1997 12(11 Suppl): p. 113-20.
<http://www.ncbi.nlm.nih.gov/pubmed/9433967>
182. Weidner W, et al. Ureaplasma infections of the male urogenital tract, in particular prostatitis, and semen quality. *Urol Int* 1985 40(1): p. 5-9.
<http://www.ncbi.nlm.nih.gov/pubmed/3883615>

183. Taylor-Robinson D. Infections due to species of *Mycoplasma* and *Ureaplasma*: an update. *Clin Infect Dis* 1996 23(4): p. 671-82; quiz 683-4.
<http://www.ncbi.nlm.nih.gov/pubmed/8909826>
184. Aitken RJ, et al. Seminal leukocytes: passengers, terrorists or good samaritans? *Hum Reprod* 1995 10(7): p. 1736-9. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/8582971>
185. Trum JW, et al. Value of detecting leukocytospermia in the diagnosis of genital tract infection in subfertile men. *Fertil Steril* 1998 70(2): p. 315-9.
<http://www.ncbi.nlm.nih.gov/pubmed/9696227>
186. Krieger JN, et al. Seminal fluid findings in men with nonbacterial prostatitis and prostatodynia. *J Androl* 1996 17(3): p. 310-8.
<http://www.ncbi.nlm.nih.gov/pubmed/8792222>
187. Weidner W, et al. Semen parameters in men with and without proven chronic prostatitis. *Arch Androl* 1991 26(3): p. 173-83.
<http://www.ncbi.nlm.nih.gov/pubmed/1872650>
188. Christiansen E, et al. Sperm quality in men with chronic abacterial prostatovesiculitis verified by rectal ultrasonography. *Urology* 1991 38(6): p. 545-9.
<http://www.ncbi.nlm.nih.gov/pubmed/1746084>
189. Giamarellou H, et al. Infertility and chronic prostatitis. *Andrologia* 1984 16(5): p. 417-22.
<http://www.ncbi.nlm.nih.gov/pubmed/6496959>
190. Leib Z, et al. Reduced semen quality caused by chronic abacterial prostatitis: an enigma or reality? *Fertil Steril* 1994 61(6): p. 1109-16.
<http://www.ncbi.nlm.nih.gov/pubmed/8194626>
191. Wolff H. The biologic significance of white blood cells in semen. *Fertil Steril* 1995 63(6): p. 1143-57.
<http://www.ncbi.nlm.nih.gov/pubmed/7750580>
192. Wolff H, et al. Impact of clinically silent inflammation on male genital tract organs as reflected by biochemical markers in semen. *J Androl* 1991 12(5): p. 331-4.
<http://www.ncbi.nlm.nih.gov/pubmed/1765569>
193. Dousset B, et al. Seminal cytokine concentrations (IL-1beta, IL-2, IL-6, sR IL-2, sR IL-6), semen parameters and blood hormonal status in male infertility. *Hum Reprod* 1997 12(7): p. 1476-9.
<http://www.ncbi.nlm.nih.gov/pubmed/9262280>
194. Huleihel M, et al. Distinct expression levels of cytokines and soluble cytokine receptors in seminal plasma of fertile and infertile men. *Fertil Steril* 1996 66(1): p. 135-9.
<http://www.ncbi.nlm.nih.gov/pubmed/8752625>
195. Shimonovitz S, et al. High concentration of soluble interleukin-2 receptors in ejaculate with low sperm motility. *Hum Reprod* 1994 9(4): p. 653-5.
<http://www.ncbi.nlm.nih.gov/pubmed/8046017>
196. Zalata A, et al. Evaluation of beta-endorphin and interleukin-6 in seminal plasma of patients with certain andrological diseases. *Hum Reprod* 1995 10(12): p. 3161-5.
<http://www.ncbi.nlm.nih.gov/pubmed/8822435>
197. Alexander RB, et al. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. *Urology* 1998 52(5): p. 744-9.
<http://www.ncbi.nlm.nih.gov/pubmed/9801092>
198. Comhaire F, et al. Diagnosis of accessory gland infection and its possible role in male infertility. *Int J Androl* 1980 3(1): p. 32-45.
<http://www.ncbi.nlm.nih.gov/pubmed/7409893>
199. Depuydt CE, et al. The relation between reactive oxygen species and cytokines in andrological patients with or without male accessory gland infection. *J Androl* 1996 17(6): p. 699-707.
<http://www.ncbi.nlm.nih.gov/pubmed/9016401>
200. Schaeffer AJ. Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. *N Engl J Med* 2006 355(16): p. 1690-8. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/17050893>
201. Wagenlehner FM, et al. Chronic bacterial prostatitis (NIH type II): diagnosis, therapy and influence on the fertility status. *Andrologia* 2008 40(2): p. 100-4.
<http://www.ncbi.nlm.nih.gov/pubmed/18336459>
202. Weidner W, et al. Therapy in male accessory gland infection--what is fact, what is fiction? *Andrologia* 1998 30 Suppl 1: p. 87-90. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/9629448>

203. Comhaire FH, et al. The effect of doxycycline in infertile couples with male accessory gland infection: a double blind prospective study. *Int J Androl* 1986 9(2): p. 91-8.
<http://www.ncbi.nlm.nih.gov/pubmed/3539821>
204. Berger R, Epididymitis. In: Holmes KK, Mardh PA, Sparling PF et al. (eds). *Sexually Transmitted Diseases, in Sexually Transmitted Diseases*. 1984, McGraw-Hill: New York. p. 650-62.
205. Berger RE, et al. Etiology, manifestations and therapy of acute epididymitis: prospective study of 50 cases. *J Urol* 1979 121(6): p. 750-4.
<http://www.ncbi.nlm.nih.gov/pubmed/379366>
206. Weidner W, et al. Acute nongonococcal epididymitis. Aetiological and therapeutic aspects. *Drugs* 1987 34 Suppl 1: p. 111-7.
<http://www.ncbi.nlm.nih.gov/pubmed/3481311>
207. [No authors listed] National guideline for the management of epididymo-orchitis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). *Sex Transm Infect* 1999 75 Suppl 1: p. S51-3. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/10616385>
208. Weidner W, et al., Orchitis. In: Knobil E, Neill JD (eds) *Encyclopedia of Reproduction*, in *Encyclopedia of Reproduction*. 1999, Academic Press: San Diego. p. 92-5.
209. Robinson AJ, et al. Acute epididymitis: why patient and consort must be investigated. *Br J Urol* 1990 66(6): p. 642-5.
<http://www.ncbi.nlm.nih.gov/pubmed/2265337>
210. Skakkebaek NE. Carcinoma in situ of the testis: frequency and relationship to invasive germ cell tumours in infertile men. *Histopathology* 1978 2(3): p. 157-70.
<http://www.ncbi.nlm.nih.gov/pubmed/27442>
211. von der Maase H, et al. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. *Br Med J (Clin Res Ed)* 1986 293(6559): p. 1398-401.
<http://www.ncbi.nlm.nih.gov/pubmed/3026550>
212. Jacobsen R, et al. Risk of testicular cancer in men with abnormal semen characteristics: cohort study. *BMJ* 2000 321(7264): p. 789-92.
<http://www.ncbi.nlm.nih.gov/pubmed/11009515>
213. Huyghe E, et al. Increasing incidence of testicular cancer worldwide: a review. *J Urol* 2003 170(1): p. 5-11.
<http://www.ncbi.nlm.nih.gov/pubmed/12796635>
214. Giwercman A, et al. Carcinoma in situ of the undescended testis. *Semin Urol* 1988 6(2): p. 110-9. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/2903524>
215. Petersen PM, et al. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. *J Clin Oncol* 1999 17(3): p. 941-7.
<http://www.ncbi.nlm.nih.gov/pubmed/10071288>
216. Eberhard J, et al. Impact of therapy and androgen receptor polymorphism on sperm concentration in men treated for testicular germ cell cancer: a longitudinal study. *Hum Reprod* 2004 19(6): p. 1418-25.
<http://www.ncbi.nlm.nih.gov/pubmed/15105386>
217. Willemse PH, et al. Altered Leydig cell function in patients with testicular cancer: evidence for bilateral testicular defect. *Acta Endocrinol (Copenh)* 1983 102(4): p. 616-24.
<http://www.ncbi.nlm.nih.gov/pubmed/6133401>
218. Nord C, et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. *Eur Urol* 2003 44(3): p. 322-8.
<http://www.ncbi.nlm.nih.gov/pubmed/12932930>
219. Eberhard J, et al. Risk factors for post-treatment hypogonadism in testicular cancer patients. *Eur J Endocrinol* 2008 158(4): p. 561-70.
<http://www.ncbi.nlm.nih.gov/pubmed/18362304>
220. Eberhard J, et al. Sexual function in men treated for testicular cancer. *J Sex Med* 2009 6(7): p. 1979-89.
<http://www.ncbi.nlm.nih.gov/pubmed/19453896>
221. Schrader M, et al. "Onco-tese": testicular sperm extraction in azoospermic cancer patients before chemotherapy-new guidelines? *Urology* 2003 61(2): p. 421-5.
<http://www.ncbi.nlm.nih.gov/pubmed/12597960>
222. Parra BL, et al. Testicular microlithiasis as a predictor of intratubular germ cell neoplasia. *Urology* 1996 48(5): p. 797-9.
<http://www.ncbi.nlm.nih.gov/pubmed/8911532>

223. Peterson AC, et al. The prevalence of testicular microlithiasis in an asymptomatic population of men 18 to 35 years old. *J Urol* 2001 166(6): p. 2061-4.
<http://www.ncbi.nlm.nih.gov/pubmed/11696707>
224. Thomas K, et al. The incidence and significance of testicular microlithiasis in a subfertile population. *Br J Radiol* 2000 73(869): p. 494-7.
<http://www.ncbi.nlm.nih.gov/pubmed/10884745>
225. von Eckardstein S, et al. Sonographic testicular microlithiasis as an indicator of premalignant conditions in normal and infertile men. *J Androl* 2001 22(5): p. 818-24.
<http://www.ncbi.nlm.nih.gov/pubmed/11545295>
226. Pierik FH, et al. Is routine scrotal ultrasound advantageous in infertile men? *J Urol* 1999 162(5): p. 1618-20.
<http://www.ncbi.nlm.nih.gov/pubmed/10524881>
227. Derogee M, et al. Testicular microlithiasis, a premalignant condition: prevalence, histopathologic findings, and relation to testicular tumor. *Urology* 2001 57(6): p. 1133-7.
<http://www.ncbi.nlm.nih.gov/pubmed/11377326>
228. Giwercman A, et al. Prevalence of carcinoma in situ and other histopathological abnormalities in testes from 399 men who died suddenly and unexpectedly. *J Urol* 1991 145(1): p. 77-80.
<http://www.ncbi.nlm.nih.gov/pubmed/1984105>
229. Miller FN, et al. Does testicular microlithiasis matter? A review. *Clin Radiol* 2002 57(10): p. 883-90.
<http://www.ncbi.nlm.nih.gov/pubmed/12413911>
230. de Gouveia Brazao CA, et al. Bilateral testicular microlithiasis predicts the presence of the precursor of testicular germ cell tumors in subfertile men. *J Urol* 2004 171(1): p. 158-60.
<http://www.ncbi.nlm.nih.gov/pubmed/14665866>
231. van Casteren NJ, et al. Testicular microlithiasis and carcinoma in situ overview and proposed clinical guideline. *Int J Androl* 2009 32(4): p. 279-87.
<http://www.ncbi.nlm.nih.gov/pubmed/19207616>
232. Buvat J, Glossaire. [Disruptions in ejaculation] In: Buvat J, Jouannet P (eds). [Ejaculation and its Disruptions.], in *Ejaculation and its Disruptions*. 1984, SIMEP: Lyon-Villeurbanne. p. 9 [Book in French].
233. Wang R, et al., Ejaculatory dysfunction. In: Comhaire FH (ed). *Male Infertility: Clinical Investigation. Cause, Evaluation and Treatment*, in *Male Infertility: Clinical Investigation. Cause, Evaluation and Treatment*. 1996, Chapman Hall: London. p. 205-221.
234. Pryor J, Erectile and ejaculatory problems in infertility. In: Hargreave TB (ed). *Male Infertility.*, in *Male Infertility*. 1997, Springer Verlag: Berlin. p. 319-36.
235. Yachia D. Our experience with penile deformations: incidence, operative techniques, and results. *J Androl* 1994 15 Suppl: p. 63S-68S.
<http://www.ncbi.nlm.nih.gov/pubmed/7721682>
236. Rudkin L, et al. Strategies for managing sexual dysfunction induced by antidepressant medication. *Cochrane Database Syst Rev* 2004(4): p. CD003382.
<http://www.ncbi.nlm.nih.gov/pubmed/15495050>
237. Abdel-Hamid IA, et al. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. *Int J Impot Res* 2001 13(1): p. 41-5.
<http://www.ncbi.nlm.nih.gov/pubmed/11313839>
238. Demyttenaere K, et al. Painful ejaculation and urinary hesitancy in association with antidepressant therapy: relief with tamsulosin. *Eur Neuropsychopharmacol* 2002 12(4): p. 337-41.
<http://www.ncbi.nlm.nih.gov/pubmed/12126873>
239. McMahon CG, et al. Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation. *J Sex Med* 2011 8(10): p. 2707-25.
<http://www.ncbi.nlm.nih.gov/pubmed/2177128>
240. Crich JP, et al. Infertility in men with retrograde ejaculation: the action of urine on sperm motility, and a simple method for achieving antegrade ejaculation. *Fertil Steril* 1978 30(5): p. 572-6.
<http://www.ncbi.nlm.nih.gov/pubmed/720646>
241. Gilja I, et al. Retrograde ejaculation and loss of emission: possibilities of conservative treatment. *Eur Urol* 1994 25(3): p. 226-8.
<http://www.ncbi.nlm.nih.gov/pubmed/8200405>
242. Jonas D, et al. The use of Midodrin in the treatment of ejaculation disorders following retroperitoneal lymphadenectomy. *Eur Urol* 1979 5(3): p. 184-7.
<http://www.ncbi.nlm.nih.gov/pubmed/87324>

243. Schill WB. Pregnancy after brompheniramine treatment of a diabetic with incomplete emission failure. *Arch Androl* 1990 25(1): p. 101-4.
<http://www.ncbi.nlm.nih.gov/pubmed/2389987>
244. Brooks ME, et al. Treatment of retrograde ejaculation with imipramine. *Urology* 1980 15(4): p. 353-5. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/7190335>
245. Hendry WF. Disorders of ejaculation: congenital, acquired and functional. *Br J Urol* 1998 82(3): p. 331-41. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/9772867>
246. Brindley GS. Reflex ejaculation under vibratory stimulation in paraplegic men. *Paraplegia* 1981 19(5): p. 299-302.
<http://www.ncbi.nlm.nih.gov/pubmed/7279433>
247. Elliott S, et al. Treatment of anejaculation. In: Colpi GM, Balerna M (eds). *Treating Male Infertility: New Possibilities*, in *Treating Male Infertility: New Possibilities*. 1994, Karger AG: Basel. p. 240-54.
248. Waldinger MD. The neurobiological approach to premature ejaculation. *J Urol* 2002 168(6): p. 2359-67.
<http://www.ncbi.nlm.nih.gov/pubmed/12441918>
249. Jankowicz E, et al. [Idiopathic autonomic neuropathy (pandysautonomia)]. *Neurol Neurochir Pol* 2001 35(3): p. 439-52.
<http://www.ncbi.nlm.nih.gov/pubmed/11732267>
250. Maurer CA, et al. Total mesorectal excision preserves male genital function compared with conventional rectal cancer surgery. *Br J Surg* 2001 88(11): p. 1501-5.
<http://www.ncbi.nlm.nih.gov/pubmed/11683749>
251. Saito K, et al. Sperm cryopreservation before cancer chemotherapy helps in the emotional battle against cancer. *Cancer* 2005 104(3): p. 521-4.
<http://www.ncbi.nlm.nih.gov/pubmed/15968690>
252. Askari HA, et al. Effect of natural antioxidants tocopherol and ascorbic acids in maintenance of sperm activity during freeze-thaw process. *Arch Androl* 1994 33(1): p. 11-5.
<http://www.ncbi.nlm.nih.gov/pubmed/7979804>
253. Chohan KR, et al. Evaluation of chromatin integrity in human sperm using acridine orange staining with different fixatives and after cryopreservation. *Andrologia* 2004 36(5): p. 321-6.
<http://www.ncbi.nlm.nih.gov/pubmed/15458552>
254. Desrosiers P, et al. Membranous and structural damage that occur during cryopreservation of human sperm may be time-related events. *Fertil Steril* 2006 85(6): p. 1744-52.
<http://www.ncbi.nlm.nih.gov/pubmed/16643911>
255. Donnelly ET, et al. Cryopreservation of human semen and prepared sperm: effects on motility parameters and DNA integrity. *Fertil Steril* 2001 76(5): p. 892-900.
<http://www.ncbi.nlm.nih.gov/pubmed/11704107>
256. Agarwal A, et al. Oxidative stress, DNA damage and apoptosis in male infertility: a clinical approach. *BJU Int* 2005 95(4): p. 503-7. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/15705068>
257. Smith KD, et al. Survival of spermatozoa in a human sperm bank. Effects of long-term storage in liquid nitrogen. *JAMA* 1973 223(7): p. 774-7. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/4739258>
258. Grischenko VI, et al. Cryopreservation of human sperm using rapid cooling rates. *Cryo Letters* 2003 24(2): p. 67-76.
<http://www.ncbi.nlm.nih.gov/pubmed/12819827>
259. Sherman JK, et al. Observations on preservation of human spermatozoa at low temperatures. *Proc Soc Exp Biol Med* 1953 82(4): p. 686-8. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/13055973>
260. Sawada Y, et al. Motility and respiration of human spermatozoa after cooling to various low temperatures. *Fertil Steril* 1967 18(6): p. 775-81. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/6073928>
261. Bahadur G, et al. Semen quality and cryopreservation in adolescent cancer patients. *Hum Reprod* 2002 17(12): p. 3157-61.
<http://www.ncbi.nlm.nih.gov/pubmed/12456617>
262. Hallak J, et al. Investigation of fertilizing capacity of cryopreserved spermatozoa from patients with cancer. *J Urol* 1998 159(4): p. 1217-20.
<http://www.ncbi.nlm.nih.gov/pubmed/9507838>

263. Clarke GN. Sperm cryopreservation: is there a significant risk of cross-contamination? Hum Reprod 1999 14(12): p. 2941-3. [no abstract]
<http://www.ncbi.nlm.nih.gov/pubmed/10601075>
264. O'Connell M, et al. The effects of cryopreservation on sperm morphology, motility and mitochondrial function. Hum Reprod 2002 17(3): p. 704-9.
<http://www.ncbi.nlm.nih.gov/pubmed/11870124>
265. Watson PF. Recent developments and concepts in the cryopreservation of spermatozoa and the assessment of their post-thawing function. Reprod Fertil Dev 1995 7(4): p. 871-91.
<http://www.ncbi.nlm.nih.gov/pubmed/8711221>
266. Woolley DM, et al. Ultrastructural injury to human spermatozoa after freezing and thawing. J Reprod Fertil 1978 53(2): p. 389-94.
<http://www.ncbi.nlm.nih.gov/pubmed/567693>

5. CONFLICT OF INTEREST

All members of the EAU Male Infertility Guidelines Panel have provided disclosure statements of all relationships that they have that might be perceived as a potential source of a conflict of interest. This information is publicly accessible through the European Association of Urology website. This document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.

